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ABSTRACT 
The remaining reservoir of effective antibiotics is running out and more and more pathogens 
are gaining resistance, even to the last line of antibiotics. Therefore, novel treatment regimens 
against bacterial infections are urgently needed. Antimicrobial peptides (AMPs) are 
expressed at mucosal surfaces and protect the host against invasive microbes. Not only are 
they efficient microbial killers but they also orchestrate additional immune responses, 
including chemotaxis and wound healing. The focus in the current work has been on the 
human cathelicidin LL-37 (encoded by the CAMP gene), which can be considered as a 
marker for the AMP-system in general. Since several AMPs with different mechanism of 
action are released simultaneously, the risk of developing bacterial resistance is very low. 
Here we propose a concept where drug-like molecules that induce the expression of AMPs 
can be used to prevent or treat infections. We suggest that this novel approach designated 
‘Host Directed Therapy’ can be used alone or together with traditional antibiotics for 
treatment of infections.  
The overall aim with this thesis was to identify novel AMP inducing compounds and to 
dissect the regulatory pathways involved in their mechanism of action.  
We set out to establish a cell-based reporter-gene-assay under the control of regulatory 
elements of the CAMP gene. Following a successful evaluation for high throughput screening 
purposes, six out of 1200 tested compounds were validated as novel inducers. One of these 
was the histone deacetylase (HDAC) inhibitor entinostat, which was found to be a potent 
inducer of LL-37 expression. Several derivatives of entinostat were synthesized and 
evaluated for LL-37 inducing activity. This strategy demonstrated which part of the molecule 
that was important for the induction. 
Entinostat was shown to regulate LL-37 via activation of the transcription factors STAT3 and 
HIF-1α. Notably, HIF-1α was found to directly bind and initiate transcription of the CAMP 
gene. In contrast, no direct binding of STAT3 to the CAMP gene promoter could be 
demonstrated. However, STAT3 was clearly involved in the regulation of LL-37 expression, 
since macrophages from a patient carrying a mutated STAT3 gene were unable to upregulate 
LL-37 upon entinostat treatment.  
Several additional regulatory pathways were discovered utilizing label free quantitative mass 
spectrometry, where protein levels were compared between unstimulated cells and cells 
treated with the AMP-inducing compounds lactose and phenylbutyrate. Next, the proteomic 
profiles were mapped to known pathways utilizing bioinformatics tools. The identified 
pathways were validated using the cell based reporter assay. The thyroid hormone receptor 
pathway, the eicosanoid signaling pathway and the steroid biosynthesis pathway could all be 
attributed to LL-37 expression.  
Together these results indicate that AMPs are strictly regulated both in homeostasis and 
during infection. The novel AMP-inducing compounds identified here should be further 
evaluated as Host Directed Therapy against infections in cellular and animal models as well 
as in relevant disease cohorts.  
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1 BACKGROUND 
1.1 INTRODUCTION 
With the arrival of antibiotics during World War II, came a weapon against microbes and 
today, we are not used to people dying from ‘simple’ bacterial infections. However, the 
microbes are winning ground and more bacterial pathogens are gaining resistance even to our 
most advanced antibiotics. Therefore, to prevent the return of the pre-antibiotic era, it is of the 
utmost importance to develop novel antibiotics and treatment regimes. This thesis describes 
the field of ‘Host Directed Therapy’, where we aim to treat infections by aiding the immune 
system in order to eliminate pathogens. By treating the host with compounds that induce 
expression of a wide variety of antimicrobial peptides (AMPs), enhancing ROS and RNS 
production and by activating autophagy, the host can efficiently destroy invading pathogens, 
inhibit their growth and prevent attachment. Moreover, induction of multiple AMPs with 
different mechanisms of action are likely more effective and also less prone to cause the 
development of microbial resistance, which is a relevant point given the emerging spread of 
multidrug resistant bacteria (Marr et al., 2006; Singh et al., 2000). 
1.2 THE IMMUNE SYSTEM  
The human immune system is typically described as two separate parts, the innate immune 
system, which we share with all multicellular organisms and the adaptive immune system, 
which is exclusive to jawed vertebrates. The adaptive immune system developed from innate 
immunity and the two systems are intertwined with each other meaning that the separation 
between the two parts is not exact, and separately, neither would be enough to defend us nor 
function in an optimal manner. The immune system is a complex entity and has always been 
at the forefront of evolution to keep up with all microbes in the surrounding. The innate 
system is the first line of defense and stops most invaders at the barrier of our body. The 
microbes that breach the barrier will be recognized by receptors on the cells of the adaptive 
system and a clonal expansion will start. The adaptive immune system is slower in action 
than innate immunity but on the other hand is much more specific and efficient when it is 
fully matured. The expansion of T- and B- cells may take up to a week for full functionality 
and during that time the innate immune system needs to hold all invaders at bay.    
1.3 INNATE IMMUNITY 
Innate immunity is the inherited defense against microbial threats towards the host and it is 
immediately activated when needed. It is evolutionary conserved and is the only immune-
defense in plants, fungi and invertebrates. In vertebrates, including humans, innate immunity 
functions as the first line of defense but also activates and recruit cells of the adaptive 
immune system. All organisms need ways to discriminate between self and non-self, hence 
there is a need for sensing of foreign molecules, such as microbial patterns and the ability to 
distinguish them from self. The sensing is followed by a response with direct antimicrobial 
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action, tissue-repair or the recruitment of clotting cells. The innate system is therefore divided 
in a sensing part and an effector part. 
1.3.1 Innate sensing  
An array of recognition receptors is included in innate immunity with two main classes; the 
Toll-like receptors (TLRs), which are situated in the cell-membrane and in the membrane of 
the lysosomes and the nucleotide-binding oligomerization domain receptors (NOD-like 
receptors), which are located inside the cells. There are also additional innate receptors, such 
as the RAGE receptor and the RIG-1-like receptors (Kierdorf and Fritz, 2013; Loo and Gale, 
2011; Xie et al., 2013). All receptors recognize certain structures or molecules, which signal 
infection or injury (Matzinger, 2002; Medzhitov, 2007, 2009). These receptors are jointly 
called pattern recognition receptors (PRRs) and they have specificity towards different 
molecular patterns. These patterns can be divided in pathogen associated molecular patterns 
(PAMPs) and damage associated molecular patterns (DAMPs) (Matzinger, 1994; Matzinger, 
2002). PAMPs are generally unique and constitute vital parts of microbes, such as 
lipopolysaccharides (LPS), lipoteichoic acid, peptidoglycans, in addition to double stranded 
RNA, single stranded DNA and unmethylated CpGs originated from microbes (Mogensen, 
2009). 
DAMPs - also known as alarmins - are released from cells under stress and consist of several 
molecules or patterns. The classical DAMP is the protein High mobility group box 1 
(HMGB1), which binds to the RAGE-receptor. Additional alarmins are self-DNA, heat-shock 
proteins, uric acid and S100 proteins (Foell et al., 2007; Lotze et al., 2007). In addition, 
AMPs can also function as alarmins. For example, LL-37 can bind to self DNA and form a 
complex, which is recognized by Toll like receptor 9 (TLR9) in plasmacytoid dendritic cells 
(pDCs), while the human neutrophil peptide-1 (HNP1) also known as α-defensin 1 regulates 
IL-1β post translationally via the P2X purino-receptor 7 (P2X7) (Chen et al., 2014; Lande et 
al., 2007). 
In response to the different stimuli described above, pro-inflammatory pathways are 
triggered. The best described pathway involves activation of ‘nuclear factor κ light chain 
enhancer of activated B cells’ (NF-κB). In addition, there are several other important 
pathways in innate immunity, such as the mitogen-activated protein kinases (MAPK) P38 and 
ERK1/2 pathways. The signal cascade of the pro-inflammatory pathways leads to an 
increased expression and release of cytokines and chemokines but also triggers expression of 
additional defense molecules, such as AMPs and mucins (Enss et al., 2000; Perez-Vilar and 
Hill, 1999) (O'Neil et al., 1999). However, the specific response will be determined by two 
major factors; the ligand and in which cell-type the response occurs (Bianchi, 2007). 
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1.3.2  Innate effectors 
1.3.2.1 Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) 
Both ROS and RNS are produced as a part of the innate defenses. The molecules exhibit a 
high reactivity by virtue of single electrons, which react with proteins, lipids and 
carbohydrates. NADPH oxidase is an enzyme, which is stored in the granules of neutrophils 
and can generate both ROS and RNS. In addition to direct microbial killing, both ROS and 
RNS are prominent signal molecules and activate several pathways of immunity, by 
activating redox sensitive proteins, such as tyrosine phosphatases which regulate the MAPK 
pathway (Neish, 2013). NF-κB is a redox sensitive transcription factor which is closely 
associated to many immune genes and functions (Gostner et al., 2013).The determination of 
Th1 or Th2 regulatory T cells is linked to the redox potential in the milieu around the naive 
T-cell, where an oxidative milieu promotes Th1 cells and versa reducing environment 
appears to promote Th2-cells (Gostner et al., 2013). Another major transcription factors 
regulated by ROS is the hypoxia induced factor 1 (HIF-1). To protect the host from damage, 
several antioxidant systems are in use, such as superoxide dismutases and the thioredoxins 
(Nathan and Cunningham-Bussel, 2013).  
1.3.2.2 Autophagy 
The mechanism of autophagy is how the cells dispose of old proteins and broken organelles 
in order to prevent them from intervening with the normal processes in the cell. Autophagy is 
a key component to keep the homeostasis of protein production and degradation. 
Interestingly, the process of autophagy recycles all material and it is therefore vital during 
starvation when less important proteins and organelles can be degraded and used for building 
parts and nutrients. However, it is also a very important pathway for clearance of intracellular 
pathogens, such as Mycobacterium tuberculosis (Mtb). In addition, autophagy have been 
demonstrated to modulate both MHC class I and class II antigen presentation (Crotzer and 
Blum, 2009; Glick et al., 2010).   
1.3.2.3 Antimicrobial peptides 
AMPs are often referred to as gene encoded antibiotics and are typically produced and 
released upon infection. They are cationic and amphipathic and as such have a preference for 
microbial cell-membranes and the main mode of action is disruption of cell-membranes 
(Zasloff, 2002). AMPs are ancient molecules in evolution and important effector molecules 
of the innate immune system. They are found throughout all branches of life, including 
archaea. The halocin S8 from Haloarchaea (Price and Shand, 2000) is an example of an 
AMP from a very primitive organism. Moreover, also bacteria express molecules with 
antimicrobial action against other bacterial species. These molecules are called bacteriocins 
and are important for the bacterial competition at mucosal surfaces (Dobson et al., 2012).  
The first antimicrobial molecule found in humans was isolated by Alexander Fleming from 
nasal secretions in 1922 and this antimicrobial protein was named ‘lysozyme’ (Fleming, 
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1922). It is highly expressed in neutrophils (PMN’s) and also present in tears and breast milk. 
This finding set off an era of novel discoveries in the field. Between 1920 and 1950 several 
articles described the isolation of molecules with antimicrobial activity from many different 
organisms, Bombinin from the frog Bombina variegate, lactoferrin from cow milk and 
purothionins from wheat, (Fernandez de Caleya et al., 1972; Groves et al., 1965; Kiss and 
Michl, 1962) . Technical limitations of the time hindered full characterization of the 
respective molecules but in 1980, the first AMPs were characterized and reported by the 
group of Hans G. Boman. These small peptides were isolated from the silk moth, Hyalophora 
cecropia and were subsequently named as ‘cecropins’ (Hultmark et al., 1980; Steiner et al., 
1981). In the beginning of the eighties the defensins were isolated from rabbit macrophages 
by the group of Robert Lehrer (Selsted et al., 1983). At the end of the 80’s Michael Zasloff 
isolated and characterized the Magainins from the African clawed frog Xenopus laevis 
(Zasloff, 1987). These discoveries indicated that AMPs were widespread in nature. To date 
2684 AMPs and proteins from different species and kingdoms have been described and in 
humans there are 112 reported antimicrobial peptides and proteins (Wang, 2014; Wang et al., 
2016b). 
AMPs share some common denominators across species. Typically, they are small (12–50 
amino acids), have a positive net-charge with an amphipathic character and are usually 
defined by their secondary structure; α-helical, β-sheets or random coils, rich in arginine and 
prolines (Lai and Gallo, 2009).   
1.3.2.3.1 Defensins  
The defensins represent an ancient family of AMPs and in contrast to the cathelicidins they 
are more than 30 different defensin genes identified in the human genome. However, only ten 
of them have been characterized on the peptide level. Defensins have been found in animals, 
plants, fungi and in some species of myxobacteria (Lehrer and Ganz, 2002; Mygind et al., 
2005; Vriens et al., 2014; Wong et al., 2007; Zhu, 2007, 2008). The defensins are synthesized 
as preproproteins and are activated by cleavage into peptides with sizes between18-45 amino 
acids. These peptides contain conserved cysteines, six in mammals and birds, eight in plants 
and vertebrates, forming disulphide bonds, which stabilize a β-sheet conformation (Carvalho 
Ade and Gomes, 2009; Ganz, 2003). The S-S bonds are however paired differently between 
the cysteine residues, giving rise to the division of the defensins into α, β and θ defensins 
(Ganz, 2003). The defensins, as a group, have been shown to have a broad and potent 
antimicrobial activity against both gram positive and gram negative bacteria, fungi and some 
enveloped viruses (Ganz, 2003). The concentration of enteric defensins can reach levels of 
above 10 mg/ml in the intestinal crypts and between 10 and 100 µg/ml in other epithelial 
cells, as determined by analysis of human skin and porcine tongue (Ganz, 2003). In a 
publication by Salzman et al. in 2003, defensins were for the first time shown to be important 
in vivo, where human α defensin-5 (HD5) enabled protection against enteric salmonellosis 
(Salzman et al., 2003). Like most AMPs, defensins act through the disruption of microbial 
cell membranes, but it has also been demonstrated that they interfere with both RNA and 
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DNA synthesis (Ganz, 2003). Interestingly, it has been reported that human β defensin-1 
(hBD-1) increases its antimicrobial activity upon reduction of its S-S bridges, most likely via 
thioredoxin, which co-localizes with hBD-1 in epithelial cells (Schroeder et al., 2011). For 
HD5, on the other hand, reduction of its S-S bonds reduces its ability to kill microbes in vitro 
and instead induces the LPS neutralizing effect and turns the peptide into an effective zinc 
chelator (Wang et al., 2016a; Zhang et al., 2013). Defensins are more than just active 
antimicrobials; some also function as alarmins, regulators of cytokines and chemo-attractants 
of monocytes and T-cells (Chen et al., 2014; Chertov et al., 1996; Sakamoto et al., 2005; 
Semple and Dorin, 2012; Territo et al., 1989).  
α-defensins 
There are six α defensins expressed in humans. Four of them are known under the name of 
human neutrophil peptide (HNP1-4). The HNPs are highly concentrated in the primary 
granules of neutrophils and expressed in B-, T- and NK-cells as well as in monocytes 
(Agerberth et al., 2000; Ganz, 2003). The human defensins 5 and 6 (HD5 and HD6) are 
expressed by Paneth cells in the small intestine in a constitutive manner. They are stored in 
granules that upon stimulation are released into the intestinal crypts, where they can reach 
concentrations of more than10 mg/ml (Bevins and Salzman, 2011; Ganz, 2003; Ouellette, 
2011). HD5 and HD6 complement each other by virtue of their separate mechanisms in the 
innate immune system. HD5 has a direct antimicrobial action by lysing bacteria, while HD6, 
interestingly, can self-assemble or aggregate into what can be defined as “nanonets”, with the 
ability to ensnare bacteria (Bevins, 2013; Chu et al., 2012; Ouellette and Selsted, 2012).  
HD5 is constitutively expressed in the female genital tract and induced in urethra by 
Neisseria gonorrhoeae infection. HD6 has also been implicated in the female genital tract 
upon the same infection (Klotman et al., 2008; Porter et al., 2005; Svinarich et al., 1997). 
Interestingly, HD5 and 6 as well as Neisseria gonorrhoeae infection have been suggested to 
facilitate HIV transmission (Klotman et al., 2008; Rapista et al., 2011).  
β-defensins 
The human β-defensins are mainly expressed in the skin and at mucosal barriers (Ganz, 2003; 
Lai and Gallo, 2009). Despite many genes encoding β-defensins in the human genome, only 
four peptide products have been characterized. hBD-1 is mainly constitutively expressed, 
while the other three β-defensins, hBD2-4, are regulated by PAMPs or DAMPs, e.g. by 
bacterial infection or injury (Nuding et al., 2013). However, we and others have demonstrated 
that also hBD-1 can be regulated, both by bacterial infection and by small molecular 
compounds (paper III) (Sorensen et al., 2005). In addition, β-defensins are expressed in the 
genital tract and interestingly hBD2-4 are down-regulated as a response to unprotected 
vaginal intercourse (Nakra et al., 2016).  
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θ-defensins 
θ-defensins are interesting molecules that only exists in old world primates. θ-defensins are 
cyclic peptides and as such the only cyclic peptides found in mammals, where they seem to 
have evolved from α-defensins. The active θ-defensin is formed by ligation of two copies of 
the θ-defensin peptide; i.e. two copies of the precursor protein are needed for one θ-defensin. 
The precursor protein is interestingly closely related to the α-defensins (Tang et al., 1999). 
Humans, chimpanzees and gorillas do not express θ-defensins, however the genes for θ-
defensins can be found in the genomes of these species. In humans the mRNA is transcribed, 
but a mutation has introduced a premature stop codon and thus the active peptide cannot be 
translated. The θ-defensins have been studied for their potential as anti-viral compounds, 
especially in the treatment of HIV (Gallo et al., 2006; Munk et al., 2003). 
1.3.2.3.2 Cathelicidins 
Cathelicidins are generally considered mammalian AMPs and at least one cathelicidin gene 
have been identified within all mammals examined. However, they have also been found in 
snakes and catfish. They are synthesized as pre-pro-peptides and the signal sequence (pre) is 
directing the pre-pro-peptide towards the designated compartment, usually destined for 
exocytosis (Gudmundsson et al., 1996). The conserved cathelin domain (pro) has a high 
similarity to the cathepsin L inhibitor cathelin and the variable C-terminal domain is the part 
that confer the antimicrobial activity (Zanetti et al., 1995). This is conferred by a four exon 
gene which in human is entitled Cathelicidin AntiMicrobial Peptide or CAMP (Gudmundsson 
et al., 1996). It is located on the third chromosome and is only ~2 kilo base pairs (kb) long 
including introns (Figure 1). Interestingly, the variable active peptide is always located in the 
fourth exon, potentially explaining why the C-terminal and active peptides of the 
cathelicidins are not evolutionary conserved (Tomasinsig and Zanetti, 2005). Humans only 
carry one cathelicidin gene and this holds true also for mouse, rat and rabbit. The peptides in 
these species are all α-helical in their secondary structure, implying that these species can 
work as model systems for studies on the human cathelicidin. The α-helical secondary 
structure of the human C-terminal domain adopts this conformation upon contact with 
microbes, experimentally demonstrated using micelles (Li et al., 2006). Possibly avoiding 
host damage by undertaking a random coil structure until activity is needed. Furthermore it 
has been shown that the helical structure is also stabilized under mimicking of in vivo 
conditions (Johansson et al., 1998).  
Cathelicidin is vital for resistance to several pathogens. For example, in mice it has been 
demonstrated that the mouse cathelicidin CRAMP is pivotal for resistance against C. albicans 
in the gut and against a sensitive strain of Group A Streptococcus in the skin (Fan et al., 2015; 
Nizet et al., 2001).  
The human cathelicidin peptide was discovered in 1995 on cDNA level and the putative 
antimicrobial peptide was named FALL-39 (Agerberth et al., 1995). However, when the 
active peptide was isolated and characterized from granulocytes it was found to be two 
residues shorter. Thus, the peptide was named LL-37, after the two leucines in the N-terminal 
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end and from the length of 37 amino acid residues. The LL-37 peptide sequence is as follows. 
NH2-LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-COOH (Gudmundsson et al., 
1996). The proform was designated as human cationic antimicrobial protein weighing 18 kDa 
or hCAP-18.  
 
 
Figure 1. Schematic representation of the CAMP gene and its translational product. Transcription factors activate 
RNA polymerase II and mediate transcription. The CAMP gene is transcribed from four exons, where Exon 1-3 
encode the cathelin domain including a sequence that signals for exocytosis. Exon four encodes the peptide with the 
antimicrobial activity, LL-37, shown by dual colors, representing the amphipathicity of the peptide. The signal 
sequence is removed after direction for exocytosis. The remaining pro-peptide is designated hCAP-18 and the active 
peptide is cleaved off by protease 3 in neutrophils and adopts an α-helical conformation.   
 
LL-37 has been shown to be potent against many different microbial species (Turner et al., 
1998), and is considered especially potent against gram negative bacteria because of the high 
affinity to LPS. LL-37 actually binds LPS with a 2:1 stoichiometry that is cooperative to its 
nature (Turner et al., 1998). Minimal inhibitory concentrations (MIC) values of LL-37 varies 
with bacteria and method used, it is however not unusual with sub-µM concentrations 
(Larrick et al., 1995). Furthermore, the activity based on the ability to achieve α-helical 
structure of LL-37 is enhanced in the presence of anions and by increasing the pH value 
(Johansson et al., 1998). It has been demonstrated that apart from the microbial killing, LL-37 
is responsible for additional effects, such as angiogenesis, apoptosis and as already 
mentioned, endotoxin neutralizing (Table 1).  
  
 
  
 8 
Table 1. Additional functions of LL-37 apart from the antimicrobial effects.  
Function Mechanism Reference  
Chemotaxis By activation of formyl peptide 
receptor-like 1 (FPRL1) and 
CXCR2 (IL-8 receptor)  
(De et al., 2000; Zhang et al., 2009) 
Apoptosis Both inducing apoptosis and 
increase life span of cells. Action 
suggested via FPRL1, P2X7, P53, 
Bax ,Bak and Bcl-2  
(Barlow et al., 2006; Lau et al., 
2006; Nagaoka et al., 2006; Ren et 
al., 2012) 
Angiogenic Via FPRL1 (Koczulla et al., 2003) 
Neutralization of endotoxin  Direct LPS binding and 
competitive binding to P2X7  
(Hu et al., 2014; Turner et al., 
1998) 
Wound healing LL-37 induce keratinocyte 
migration via EGFR activation 
(Heilborn et al., 2003; Shaykhiev et 
al., 2005; Tokumaru et al., 2005) 
Histamine release Via G protein-phospholipase C-
dependent manner 
(Niyonsaba et al., 2001) 
Leukotriene B4 release Via activation of FPR2/ALX (Wan et al., 2011; Wan et al., 2007; 
Wan et al., 2014a) 
Increase in ROS production and 
release of α defensins 
By enhanced production of IL-8 (Zheng et al., 2007) 
Modulation of dendritic cell 
function 
Via regulation of TLR ligands (Kandler et al., 2006) 
Macrophage differentiation  (van der Does et al., 2010) 
Induction of autophagy  (Rekha et al., 2015) 
Increase phagocytosis Via activation of integrin Mac-1 (Wan et al., 2014b; Zhang et al., 
2016) 
 
1.3.2.3.3 Antimicrobial proteins  
The S100 calcium proteins are a large group of structurally related proteins of which several 
have demonstrated to exhibit antimicrobial activity. Calprotectin consists as a dimer of 
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S100A8 and A9 and is highly abundant in the cytoplasm of neutrophils (Edgeworth et al., 
1991). The mechanism of action is attributed to its chelating properties, where it deprives the 
microbes of essential minerals (Clohessy and Golden, 1995; Damo et al., 2013; Sohnle et al., 
2000). Another S100 protein with antimicrobial activity is psoriasin, which was first isolated 
from psoriatic lesions, where it is drastically induced. Interestingly, psoriatic lesions are 
seldom infected despite the prolonged exposure to possible invasive pathogens, likely due to 
chelating of divalent zinc ions (Glaser et al., 2005). Psoriasin is also expressed during 
differentiation of mammary epithelial cells, and it is associated with poor prognosis in 
estrogen negative breast cancer tumors (Emberley et al., 2003; Vegfors et al., 2012).  
Lactotransferrin is another chelating protein that was first identified to act as a transporter for 
iron in milk and blood. However, it is now known to be active against viruses, bacteria and 
fungi, and the main mechanism is sequestering of irons from the milieu and hence to starve 
the microbes (Bullen et al., 1972; Jenssen and Hancock, 2009).  
Contrary to AMPs, many antimicrobial proteins are negatively charged, hence the chelating 
properties, which seem to be a general route of antimicrobial activity. In fact all metal 
sequestering proteins can be considered to be antimicrobial by nature, disregarding their 
actual function.  
Regenerating islet-derived proteins (Regs) from the superfamily of C-type lectins have been 
detected in many different cell-types and are often associated with differentiation and 
proliferation (Parikh et al., 2012). Generally, the Regs are thought of as intestinal proteins and 
have been demonstrated to keep the small intestinal epithelial cells sterile (Vaishnava et al., 
2011). In mice it has been demonstrated that signal transducer and activator of transcription 3 
(STAT3) is a key regulator of Reg3γ in both intestinal and lung epithelia, and that Reg3γ is 
vital in MRSA pneumonia clearance (Choi et al., 2013; Lee et al., 2012; Murano et al., 2014). 
Also in humans it has been demonstrated that several Reg genes are upregulated upon 
STAT3 activation (Murano et al., 2014). The killing mechanism of Reg3γ action have not yet 
been determined (Gallo and Hooper, 2012). Reg3α is bactericidal for Gram-positive but not 
Gram-negative bacteria, which is explained by the fact that LPS blocks the ability of Reg3α 
to form pores in bacterial membranes (Mukherjee et al., 2014). Reg4 is less studied but is 
strongly associated with colorectal cancer (Kawasaki et al., 2015). 
Histones are proteins that are known to aid in the packaging of DNA in the cell nucleus. In 
addition, they also have antibacterial properties, where peptides derived from the larger 
histone proteins have been demonstrated to inhibit bacteria in vitro. They are also a major 
part of the neutrophil extracellular traps (NETs) and as such also inhibit infection (Kawasaki 
and Iwamuro, 2008). 
Ribonucleases are responsible for degradation of RNA in the cell and six out of eight have 
been reported to be involved in host defenses, RNases 2, 3, 5, 7, and 8 (Wang, 2014).  
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1.3.2.4 Linking innate and adaptive immunity  
In addition to their capacity to directly kill microbes, the innate effectors (AMPs, ROS and 
RNS) can all be described as linkers to the adaptive immune system, which via the activation 
of cytokines, chemokines and specific AMPs continue to strengthen defenses by recruiting 
cells of both the innate and adaptive immune system.  
1.3.3 Innate immune cells 
1.3.3.1 Epithelial cells 
The first innate defenses that any microbe will face are the physical barriers of the host, i.e. 
the skin, the eyes, the mouth, lungs and the lining of the gut. A part of this defense is 
epithelial cells, which are able to mount an effective defense against any microbial attack. 
Epithelial cells are covered by a layer of mucins, building the mucous membrane, as in the 
gut lining (Perez-Vilar and Hill, 1999). The mucin layer harbors several effector molecules, 
such as AMPs that are able to eliminate potential pathogens. The mucin layer consists of the 
highly glycosylated mucin proteins, which forms a virtually impassible gel-like structure. The 
mucus layer is replenished by special epithelial cells designated goblet cells. The result of this 
replenishment from below is a near sterile environment closest to the epithelial cells. The fact 
is that very few of the microbes we encounter every day will ever be in proximity to the 
epithelial cells. Even in the small intestine, where the mucus layer is thin, it has been 
demonstrated that bacteria is kept at distance from the epithelial cells by secretion of the 
antimicrobial protein Reg3γ (Vaishnava et al., 2011). If the epithelial layer or the mucosal 
layer is damaged, a pathogen may reach a site, where it can infect or invade. Epithelial cells 
are decorated with PRRs, which recognize PAMPs or DAMPs and expression and release of 
cytokines and chemokines is initiated. This leads to recruitment and activation of other 
immune cells, such as antigen presenting cells. Interestingly, TLR4 in intestinal epithelial 
cells are located on the basal side of the cells to avoid unnecessary activation by LPS (Hornef 
et al., 2003). Most of our barriers are covered by commensal bacteria specific to the place of 
colonization, helping the host by competing with pathogens for both nutrients and habitation. 
Moreover, it has been demonstrated that many of the commensal bacteria are inducing the 
expression of AMPs to which the commensal bacteria are resistant to and in that way keep 
pathogenic competitors at bay (Bevins, 2005; Kamada et al., 2013). The number of species in 
the natural flora of the gut increases with the distance from the stomach and in the colon the 
number of commensal bacteria reaches 10 to the power of 13 (Sartor, 2008). In contrast, the 
human skin barrier is more arid of commensals. Instead of the mucus layer seen in eyes, 
intestine and lung, the skin has the apoptotic layer of keratinocytes, which stops invading 
pathogens with its hard exterior. In skin, the AMPs are mainly produced when the barrier is 
broken, damaged or infected. For example, cathelicidin and hBD1 is constitutively expressed 
at low levels but may be induced together with hBD2-4 upon infection or damage (Kenshi 
and Richard, 2008).  
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1.3.3.2 Polymorphonuclear Granulocytes (PMNs) 
PMNs makes up 50-70 % of all leukocytes in humans and are named for their small vesicles 
or granules, which can be detected upon Hematoxylin staining of blood smear (Borregaard et 
al., 1987). Of the granulocytes around 99% are neutrophils and 1% consists of eosinophils, 
basophils and mast cells. The neutrophils are the first immune cells recruited to a site of 
infection or injury, where they immediately destroy microbes by phagocytosis or by releasing 
their granular content. The granules contain high concentrations of AMPs (α-defensins and 
hCAP-18) and additional proteins with antimicrobial activity, such as 
bactericidal/permeability-increasing protein and Lysozyme. The AMP concentration in the 
phagocytic vacuoles reaches concentration above 10 mg/ml (Ganz, 2003). The granules also 
contain proteases such as protease 3, which has been shown to cleave the human cathelicidin 
pro-form hCAP-18 into the cathelin domain and the active peptide LL-37 (Sorensen et al., 
2001). The neutrophils, besides their granules, carry disassembled NADPH oxidase 2 
separated in the cytosol and in the membrane which upon stimuli readily can be assembled 
and generate an oxidative burst as a general defense. Neutrophils can undergo what is called 
NETosis, where they in a suicidal fashion spew out NETs, a sticky entity made up of 
chromatin and decorated with AMPs, trapping microbes like flies in a spider web (Brinkmann 
and Zychlinsky, 2007; Sorensen et al., 2001). 
1.3.3.3 Macrophages 
Monocytes are circulating in the blood stream and lymphatic system, and depending on 
stimuli they differentiate into either macrophages or myeloid dendritic cells. 
Macrophages are found in many tissues as specialized cells with phagocytic properties. They 
have different names depending on the tissue; e.g.Kupffer cells in the liver, Langerhans cells 
in the skin and alveolar macrophages in the lungs. The macrophages are professional 
phagocytes of bacteria and present antigens from engulfed and degraded bacteria. Thus, 
macrophages can sense danger signals and convey immunological signals as well as engulf 
and kill bacteria. The circulating macrophages traverse the body to sites of infection upon 
stress signals. There are also stationary macrophages present in the tissues, which are often 
the first cells that a pathogen encounters after invasion. Upon recognition they start to express 
and release cytokines, leading to recruitment of PMNs and cells from the adaptive immune 
system (Medzhitov, 2007). Macrophages can be divided in two subtypes, the M1 and M2 
types, where the M1 is more pro-inflammatory and M2 ameliorate inflammation and drive 
tissue repair (tolerogenic phenotype) (Mills, 2012). Macrophages can also be used as 
intracellular reservoirs for certain bacteria, such as Mtb, which after phagocytosis is able to 
block the intracellular killing machinery. Notably, it has been shown by our group that Mtb 
downregulates the expression of the human cathelicidin LL-37 in macrophages (Rekha et al., 
2015).  
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1.3.3.4 Th17 cells 
Th17 cells are a subset of T-helper cells with the ability to produce IL-17, hence the name of 
the cell. In addition to IL-17, Th17 cells also produce IL-22 and together these cytokines 
orchestrate the mucosal immune-response to many pathogens. Th17 cells have been 
implicated in both induced clearance of pathogens and autoimmune diseases. Interestingly, 
various microbial species seem to induce the differentiation of naive T-cells into the Th17 
cell type where, Propionibacterium acnes and Klebsiella pneumoniae in addition to the fungi 
Candida albicans are three examples (Korn et al., 2009). In psoriatic plaques it has been 
demonstrated that Th17 cells are increased and considered to correlate with the severity of the 
disease (Pène et al., 2008). For Th17 differentiation to take place, STAT3 is central. 
Interestingly, patients with Hyper IgE syndrome (HIES) have a loss of function mutation in 
the gene encoding STAT3 and consequently lack IL-17 producing T helper cells (Bevins, 
2005). Since Th17-cytokines have been shown to induce AMP-expression in epithelial cells, 
a lack of these cytokines may explain why infections with specific bacteria, including 
Staphylococcus aureus are so frequent in HIES patients (Milner et al., 2008).  
1.3.3.5 Natural Killer cells, Dendritic cells, Eosinophils, Basophils and Mast cells   
NK-cells are responsible for elimination of autologous (endogenous) cells that have been 
infected with a virus or turned into dangerous tumor cells (Vivier et al., 2008). Dendritic cells 
are antigen presenting cells that constantly patrol the tissues and sample antigens, which are 
presented. DCs express most PRR’s and are excellent antigen presenting cells, which rapidly 
may reach a lymph node, where they present the antigens to B- and T-cells (Medzhitov, 
2007). Eosinophils, basophils and mast cells are part of PMNs but carry other defensive 
molecules in their granules. They are all closely associated to inflammation and allergy and 
they are regulators of both innate and adaptive immunity. They are also important in the 
defense against parasites such as helminths and ticks. Interestingly, eosinophils as well as 
mast cells are able to produce NETs (Rosenberg et al., 2013; Stone et al., 2010; Voehringer, 
2013; Wernersson and Pejler, 2014).  
1.4 GENE REGULATION 
In each cell, DNA is stored that have the blueprint to make up an entirely new, albeit 
“cloned” individual. In humans this blueprint contains some 20 000 genes and not all of them 
can be expressed at the same time. The active genes in a cell are quite different if you 
compare for example a macrophage to an adipocyte. Subsequently the question arrives, what 
determines, which genes should be transcribed in time and in space?  
DNA is packed in the nucleus wrapped around histones. This histone-DNA complex is 
designated nucleosomes, which can be further condensed until it reaches its most compact 
form, which can be seen during mitosis, the metaphase chromosome. During this phase no 
transcription can take place.  
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The active genes are sitting in the relaxed chromatin structure designated as euchromatin, 
while the more rigid structure with inactive genes is named heterochromatin or the 30 nm 
fiber.   
How tightly wrapped the DNA is around the histones depends on epigenetic factors, usually 
acetyl- and methyl-groups on the different histones. For DNA to be transcribed it needs to be 
accessible to transcription factors (TFs), which are proteins that bind DNA and initiate or 
repress transcription of genes. Therefore, almost all active genes in a cell are located in 
stretches of euchromatin and the promoters of the genes are located between two 
nucleosomes (Consortium, 2012; Thurman et al., 2012).    
DNA is transcribed into RNA by RNA polymerases I-III. RNA polymerase I and III produce 
the different RNA subunits of the ribosomes, while RNA polymerase II is the one responsible 
for transcription of all genes destined for translation.  
RNA polymerase II is not able to initiate transcription by itself instead it needs additional 
proteins to coordinate and activate transcription, including TFs. TFs contain a DNA binding 
domain, recognizing specific nucleotide-sequences on the DNA string, so called TF binding 
motifs. In the simplest scenario, a TF binds the designated site and recruits RNA polymerase 
II and additional co-activators, which will initiate transcription. Less simple scenarios include 
TFs functioning as repressors or recruitment of large complexes that can both unwind and 
condense the chromatin.  
Most TFs are activated through posttranslational modifications or simply by their induced 
expression. Some TFs, however, need an endogenous or exogenous ligand to induce 
binding/transcription. These are called nuclear receptors and several of them seem to be 
essential for CAMP gene expression (paper IV) (Gombart et al., 2005; Kulkarni et al., 2016; 
Park et al., 2014).  
What ultimately decides which genes should be transcribed to mRNA are a complex system, 
consisting of chromatin condensation, transcription factors and various stimuli.  
1.4.1 Regulation of antimicrobial peptides 
The identified regulatory pathways of AMP expression is depending on whether the peptide 
is needed constantly or only during challenge. Thus, some AMPs are constitutively 
expressed, some are inducible and some are both. Several mechanisms that govern AMP-
expression will be discussed below. 
The regulatory pathways of AMPs depend on several factors, for instance, which PRR is 
activated, which microbe is infecting and the responsive tissue. For example, hBD1 is kept at 
a constitutive expression by HIF-1 in the intestine, where oxygen pressure often reaches 25 % 
of normoxia (Kelly et al., 2013). Another tissue specific pathway is the activation of the taste 
receptor for bitterness, T2R38, which results in induced expression of hBD2 in the upper 
airway epithelium and in the oral cavity (Gil et al., 2015).  
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Several post-translational modifications are responsible for AMP regulation. Processing is for 
instance a vital way of regulating AMPs. LL-37 needs to be cleaved from the pro-peptide 
hCAP-18 to reach its active state. Recently Koro et al. demonstrated that LL-37 can be 
carbamylated at 7 different residues and that the carbamylation has profound effects on the 
peptide and its signaling pathway (Koro et al., 2016).  
Citrullination is another post translational modification that can alter the effects of LL-37. It 
has been demonstrated to reduce the binding capacity to LPS, hence reduce the beneficial 
effects of LL-37 during sepsis (Koziel et al., 2014). Further, the antimicrobial effect against 
Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae is reduced 
by citrullination. Citrullinated LL-37 has been found to be more efficient in recruiting 
monocytes and is also more likely to be degraded by proteases (Kilsgard et al., 2012). 
There is a difference in storage and expression of AMPs between neutrophils and epithelial 
cells. In neutrophils there are minor transcription and translation going on after maturation, 
instead all active polypeptides are stored in granules and are released upon specific stimuli. In 
epithelial cells there are no granules that can keep the peptides from harming the cell, so 
instead they are expressed and continuously released. AMP activation usually occurs upon 
infection, inflammation and wounding (Hancock and Diamond, 2000; Sorensen et al., 2003). 
This is facilitated by recognition of PAMP and/or DAMP molecules (Matzinger, 2002). This 
recognition will trigger a pro-inflammatory response, recruiting immune cells and initiate the 
expression of several immune genes. It has also been demonstrated that AMPs can be 
induced by wound-healing factors, such as insulin-like growth factor I and transforming 
growth factor α, probably in an effort to keep the damaged barrier sterile until the repair is 
finalized (Sorensen et al., 2003).  
LL-37 is also regulated by parathyroid hormone (Muehleisen et al., 2012) and by several 
steroid hormones, such as vitamin D (Wang et al., 2004b), thyroid hormone (paper IV), 
estrogen (Park et al., 2014) and glucocorticoids (paper I) (Jensen et al., 2011; Kulkarni et al., 
2016). The short chain fatty acid butyrate, a bacterial fermentation product, is readily 
produced in the gut and able to induce cathelicidin expression both in vitro and in vivo in a 
rabbit model (Raqib et al., 2006; Schauber et al., 2003).  
1.4.1.1 Host Directed Therapy 
A highly effective immune-system needs to be tightly regulated, in order to prevent attack on 
“self” or unnecessary wasting of energy after the intruder is eliminated. Therefore we have 
several regulatory pathways that keep the AMPs at bay or release them upon invading 
pathogens. Usually this regulation is exactly what the body requires, however, the peptides 
can be dysregulated in various diseases. We work on a concept that we designate “host 
directed therapy” based on the application of small molecular compounds that can induce 
AMPs in various tissues.  
Conceptually it has been shown that supplementation of vitamin D to primary immune 
deficient patients significantly reduced the use of antibiotics in the treated group (Bergman et 
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al., 2012). Furthermore, adjunctive therapy with phenylbutyrate (PBA) and vitamin D to 
tuberculosis patients significantly reduced the time to sputum conversion and the clinical 
score (Mily et al., 2015). Recently, it was shown that the levels of AMPs was increased in 
saliva and plasma after 14 weeks of vitamin D supplementation in athletes (He et al., 2016). 
Host directed therapy is meant to be an alternative or complement to classical antibiotic 
treatment and hence the question arise, what happens if the pathogens gain resistance to the 
AMPs? This is a valid question which should be contemplated. The fact is that many 
pathogens today are resistant to specific AMPs, at least during in vitro conditions, when a 
single peptide is tested alone (Cole and Nizet, 2016). However, the system is evolutionary 
ancient and multi-resistance towards the combined action of many AMPs has not been found. 
Our concept of inducing multiple AMPs with different mechanisms of action, rather than 
administering a single peptide would be more efficient from a resistance point of view. This 
is supported in several reports showing that the peptides are co-regulated (paper III) (Aberg et 
al., 2008; Hau et al., 2013; Ong et al., 2002; Sarker et al., 2011).  
Small molecular compounds that are known to regulate AMP expression are not only vitamin 
D and PBA but also, for example, mimosine extracted from the Leucaena leucocephala seed, 
which stabilizes HIF-1α and thereby increase LL-37 expression (paper III) (Fan et al., 2015). 
Endoplasmic reticulum stress is also a potent inducer of LL-37 expression and molecules like 
tunicamycin induce endoplasmic reticulum stress and LL-37 (Park et al., 2011). Small 
molecule AMP regulators are listed in Table 2. 
.  
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Table 2. List of small molecular compounds regulating AMPs. 
 
 
Compound ↕AMP Mechanism  Reference Type of compound 
Mimosine ↑LL-37 Stabilizes HIF-1α (Fan et al., 2015) Alkaloid 
Vitamin D ↑LL-37, ↑hBD1 Activates VDR (Wang et al., 2004b) Steroid hormone 
Butyrate, PBA and 
trichostatin 
↑LL-37 HDAC inhibition, 
Activates PU.1 and 
VDR. Discussed in 
paper IV 
(Kulkarni et al., 2015; 
Schauber et al., 2003) 
HDAC inhibitors, 
butyrate is a 
fermentation product 
of gut microbiota 
Tunicamycin and 
thapsigargin 
↑LL-37 Activation of 
endoplasmic reticulum 
stress response 
(Park et al., 2011)  
T3 and T4 ↑LL-37 Activation of the 
thyroid hormone 
pathway. 
Paper IV Active form of thyroid 
hormone and its 
precursor form, 
respectively 
Tiratricol, clobetasol, 
auranofin, isovaleric- 
and isobutyric-acid 
↑LL-37  Paper I T3 analogue, 
corticosteroid, 
antirheumatic agent, 
PBA derivatives  
Litocholic acid ↑LL-37 VDR and FXR 
activation 
(Termen et al., 2008) Secondary bile acid 
Lactose ↑LL-37 Mechanism discussed 
in paper IV 
(Cederlund et al., 2013) Sugar 
Entinostat ↑LL-37 and 
↑hBD1 
Activation of STAT3 
and HIF-1α 
Paper II and III Aroylated phenylene 
diamine, HDAC 
inhibitor 
Betamethasone 
valerate, triamcinolone 
acetonide 
↓hBD2-3, 
↓psoriasin, 
↓RNase 7 and 
↓LL-37 
 (Jensen et al., 2011) Corticosteroid 
Pimecrolimus ↓hBD3 and 
↓LL-37 
 (Jensen et al., 2011) Immunomodulatory 
Dexamethasone ↓LL-37  (Kulkarni et al., 2016) Corticosteroid 
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1.4.2 Dysregulation of antimicrobial peptides in disease 
Antimicrobial peptides have been reported to be dysregulated in diseases ranging from 
autoimmune diseases to bacterial infections as well as in various cancers. During shigellosis 
the Shigella bacteria downregulate the expression of LL-37 and hBD1and 3 and thereby 
evade killing and growth inhibition, facilitating further invasion (Islam et al., 2001; Sperandio 
et al., 2008). This downregulation can, however, be overcome by the use of an inducer, such 
as PBA (Sarker et al., 2011). Mtb is an intracellular pathogen able to inhibit autophagy, a 
mechanism important for elimination of intracellular bacteria. Rekha et al. reported that the 
active form of vitamin D and PBA re-activate autophagy in an LL-37 dependent fashion 
(Rekha et al., 2015). Neisseria gonorrhoeae is also able to downregulate the expression of 
LL-37 and the effect seems to be correlate with the virulence of the strain (Bergman et al., 
2005). Patients with Papillon-Lefèvre syndrome (PLS) syndrome have a mutation in the 
cathepsin C gene. Cathepsin C is activating neutrophil elastase, cathepsin G, neutrophil serine 
protease 4, and protease 3. Protease 3 is the main processing enzyme of LL-37 in neutrophils 
(Sorensen et al., 2001). These patients are characterized by palmar hyperkeratosis and by 
severe periodontitis. Interestingly, PLS patients have the same number of neutrophils 
recruited to infections as healthy controls. However, there is a complete lack of LL-37 in the 
neutrophils of PLS patients but the inactive precursor protein, hCAP-18 is abundant (Eick et 
al., 2014). Morbus Kostmann disease is also characterized with severe periodontitis and it has 
been demonstrated that there is reduced levels of both LL-37 and HNP1-3 in the neutrophils 
of these patients (Putsep et al., 2002).   
Patients with autoimmune diseases often have increased expression of AMPs, which is 
considered to be a consequence of the increase of DAMPs from the injured tissue. For 
example, in psoriatic lesions the cathelicidin LL-37 is upregulated, possibly as a response to 
tissue stress (Frohm et al., 1997). As discussed earlier, AMPs are also acting as DAMPs or 
alarmins and LL-37 can bind to self DNA in pDCs and as a complex act as an activator of 
TLR9, inducing the expression and release of type 1 interferon and hence drive the 
inflammation (Lande et al., 2007). In rosacea and systemic lupus, LL-37 is also upregulated 
and is proposed to drive the inflammation by recruitment of mast cells (Muto et al., 2014; 
Yamasaki et al., 2007). Another disorder with dysregulation of AMPs is Crohn's disease. This 
is especially associated with the expression of enteric α-defensins in the gut mucosa 
(Wehkamp et al., 2004) and to an altered microbiota in addition to a genetic disorder of the 
nucleotide-binding oligomerization domain-containing protein 2 (NOD2) receptor (Hugot et 
al., 2001; Kobayashi et al., 2005). The sensing mechanism exerted by NOD2 is 
malfunctioning and the normal antibacterial response is downregulated. The barrier function 
is disturbed and activation of compensatory pro-inflammatory pathways occur, however 
leading to an overcompensation, with a chronic inflammation in the gut as a result (Philpott et 
al., 2014).   
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1.5 TRANSCRIPTION FACTORS INVOLVED IN THE REGULATION OF LL-37 
1.5.1 Vitamin D Receptor 
The vitamin D receptor (VDR) is a nuclear receptor which dimerizes with retinoid X receptor 
(RXR) to initiate transcription. The main activating molecule is 1,25-dihydroxyvitamin D3 or 
calcitriol, a metabolite of the pro-hormone, vitamin D (Miller, 2016). It has also been 
demonstrated that VDR can use the secondary bile acid, litocholic acid (LCA) as well as PBA 
as a ligand (Adachi et al., 2005; Kulkarni et al., 2015). VDR is the most studied TF when it 
comes to regulation of the antimicrobial peptide LL-37 and binds to the promotor of the 
CAMP gene that has been shown in several chromatin immune precipitation (ChIP) 
experiments (Gombart et al., 2005; Seuter et al., 2013; Termen et al., 2008; Wang et al., 
2004b) and CAMP expression is induced in vitro upon 1,25-dihydroxyvitamin D3 treatment 
(Gombart et al., 2005; Wang et al., 2004b). Vitamin D has also been demonstrated to induce 
the gene encoding human β-defensin 2 (hBD2) (Wang et al., 2004b). 
Interestingly, only the human cathelicidin gene CAMP is equipped with a VDR binding site, 
a late evolutionary trait that possibly could reflect the connection between immunity, ambient 
UV-exposure and the subsequent increase in vitamin D levels that the loss of fur facilitated.  
1.5.2 STAT3  
Signal transducer and activator of transcription (STAT) 3 has been associated with various 
cancers, including solid tumors and blood-cancer (lymphoma, leukemia). Since STAT3 is 
activated in a number of tumor types, it has been associated with cancer in general. A list of 
STAT3 associated cancer types can be found in Buettner et.al. (Buettner et al., 2002).  
Activation of STAT3 usually occurs through activation of Janus Kinases (JAKs) by 
cytokines, and JAK in turn activates STAT3 through phosphorylation. Phosphorylated 
STAT3 will dimerize and translocate to the nucleus, where it regulates genes important for 
proliferation, apoptosis and differentiation (Hirano et al., 2000; Li et al., 2010; Sherry et al., 
2009). STAT3 is also regulated via many different cytokines and is thereby involved in the 
regulation and control of both adaptive and innate immunity. The general consensus is that 
STAT3 exhibits anti-inflammatory properties and thereby promotes tumor evasion by 
directing the anti-tumor immune response towards tolerance. Inhibition of STAT3 has been 
proposed as a novel anti-cancer-treatment by activating the immune-response against the 
tumor (Wang et al., 2004a). More recent data have indicated that gain of function mutations 
in STAT3 leads to an early onset of autoimmune diseases and that loss of function results in 
immunodeficiency (Casanova et al., 2012; Forbes et al., 2016; Milner et al., 2015).One 
example of loss of function mutations in the STAT3 gene is the causative mutation of HIES 
(Holland et al., 2007). This disease is characterized with skeletal malformations, recurrent 
staphylococcal skin abscesses, eczema and pulmonary infections as well as intestinal 
problems (Freeman and Holland, 2008, 2010). In a report from our group, Cederlund et.al 
found that HIES patient failed to produce and release AMP during colonization and bacterial 
infection in the nasopharynx (Cederlund et al., 2011). 
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STAT3 is known to regulate several AMPs, including the Regs from the superfamily of C-
type lectins, as well as the S100A7 protein (Choi et al., 2013; Hulse et al.; Lee et al., 2012; 
Murano et al., 2014). We report the novel finding that entinostat-mediated LL-37 expression 
is regulated via STAT3 (paper III). 
1.5.3 HIF-1 
Hypoxia inducible factor 1 is a transcription factor, which is activated upon oxygen 
deprivation and is responsible for the cells emergency response. It has also been linked to 
immunity, wound repair and regeneration (Andrikopoulou et al., 2011; Cramer et al., 2003; 
Peyssonnaux et al., 2005; Zhang et al., 2015). HIF-1 functions as a heterodimer with α and β 
subunits. The β -subunit is constitutively expressed and not activated upon oxygen 
deprivation. The α-subunit is on the other hand inducible on transcriptional level and also 
stabilized during low oxygen levels. The α-subunit has a proline residue that is hydroxylated 
by HIF prolyl-hydroxylases (HPDs). The hydroxylated proline residue will readily be 
ubiquitinated and, hence, HIF-1α will be degraded. HPD uses oxygen as a cofactor and, 
therefore, during hypoxia, HIF-1α will be stabilized, e.g. not degraded, and hypoxia induced 
transcription will be initiated. HIF-1 can however be activated also when the oxygen level is 
sufficient. Usually this occurs through inhibition of the HPDs, which is the case for the HPD-
inhibitor mimosine (Warnecke et al., 2003). Binding of STAT3 to HIF-1α will competitively 
stop ubiquitination by the von Hippel-Lindau tumor suppressor protein (pVHL) and hence 
stabilizes HIF-1α, as discussed in paper III and in Jung et al. (Jung et al., 2008). We also 
reveal that STAT3 activation increases the transcription of HIF-1α. Notably HIF-1α is further 
stabilized by acetylation of the lysine residue, K709 (Geng et al., 2012), a posttranslational 
modification that possibly may facilitate through the use of histone deacetylase (HDAC) 
inhibitors (HDACi). The constitutive expression of intestinal hBD1 has been demonstrated to 
be entirely dependent on HIF-1(Kelly et al., 2013).  
1.5.4 PU.1 
PU.1 is a transcription factor encoded by the SPI1 gene and is tissue specific to myeloid cells 
and generally only active during immune cell development, such as during macrophage 
differentiation from human peripheral blood monocytes (Celada et al., 1996). This 
differentiation usually takes place after PRR signaling, when there is a need for macrophages 
with elevated AMP expression (Mosser and Edwards, 2008).  
PU.1 binds to an element designated as a PU-box, which can be found in the promoter of the 
CAMP gene and ChIP analysis revealed binding of PU.1 to this site (Termen et al., 2008).  
1.5.5 Thyroid Receptor 
Thyroid hormones and their receptors have been described as a part in the regulation of 
immunity (De Vito et al., 2011), including regulation of the CAMP gene (paper IV). It also 
regulates chemotaxis, phagocytosis, reactive oxygen species (ROS) production, and cytokine 
synthesis and release (De Vito et al., 2011). The thyroid hormone receptor (TR) is most 
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active, when it dimerizes with RXR (Zhang and Lazar, 2000). Interestingly, the TRα subunit 
can be acetylated at three lysine residues in the DNA binding domain, which increases 
binding affinity. The acetylation occurs upon treatment with the ligand T3 (Sanchez-Pacheco 
et al., 2009) a posttranslational modifications that possibly can be facilitated through the use 
of HDAC inhibitors.  
1.5.6 Estrogen Receptor 
There are two genes encoding the estrogen receptor (ER) subunits, ESR1 and ESR2 encoding 
ERα and ERβ. These subunits are tissue specifically expressed and the functioning receptor 
can be both a homo- and hetero- dimer. The active form of estrogen and the ligand of ER is 
17β-estradiol.  
Estrogen hormone and ERβ have been demonstrated to be involved in the regulation of the 
cathelicidin LL-37 and also regulate immune cells (Kovats, 2015; Park et al., 2014). In paper 
IV, the ERα pathway was identified, suggesting an involvement in the regulation of the 
CAMP gene.  
1.6 HDACS AND HDAC INHIBITORS  
Post translational modifications of proteins are another way of regulating protein turnover 
and function. The most common modifications are phosphorylation, acetylation, N-linked 
glycosylation, amidation, hydroxylation and methylation (Khoury et al., 2011). However, 
there are many other post translational modifications, just to mention a few, SUMOylation, 
ubiquitination and adenylation (Falkenberg and Johnstone, 2014). Acetylation either occurs at 
the N-terminal end of a protein or at a lysine residue. Removing the lysine acetylation is 
carried out by a class of enzymes designated as HDACs or KDACs (histone deacetylases or 
lysine deacetylases) (Falkenberg and Johnstone, 2014). HDACs have the main function of 
removing an acetyl group on the lysine residue of proteins as opposed to histone acetyl 
transferases (HATs). A majority of the known acetylated lysine containing proteins is de 
facto histones and the deacetylation of these proteins condenses the chromatin structure, 
resulting in decreased transcription. HATs work on the same proteins but in the opposite way, 
leading to equilibrium of acetylated and non-acetylated histones (Falkenberg and Johnstone, 
2014). Typically, inhibition of the HDACs is thought to increase gene expression by altering 
the equilibrium towards a more open chromatin structure. This is however not the case since 
almost the same amount of genes are both up- and down-regulated upon treatment with an 
HDAC inhibitor (Falkenberg and Johnstone, 2014). The interplay of histone modifications is 
intricate and HDACs would probably be viewed in the context as a part of chromatin 
remodeling multiprotein complexes, where the action is dependent on the complex rather 
than on the specific HDAC. These remodeling complexes are often recruited by TFs and 
hence initiate histone remodeling (Lai and Wade, 2011; Muchardt and Yaniv, 1999) (Figure 
2). There are 18 mammalian HDACs, which are subdivided into class I, IIa and b, III and IV 
depending on sequence homology to the original yeast enzymes. All but the class III enzymes 
are Zinc dependent for their activity, instead class III is dependent on NAD
+
. The protein 
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names are HDAC followed by a number except for the class III again, which are designated 
as sirtuins. Interestingly, the gene regulation is specific for the different HDACs, for example, 
HDACs of class I are generally associated with regulation of innate immune genes, while 
class IIa regulates adaptive immune genes. The enzymes HDAC1-3 of class I are inhibiting 
pro-inflammatory cytokine production and TLR signaling. HDAC3 for instance inhibits NF-
κB signaling through deacetylation of the p65 NF-κB subunit (Chen et al., 2001). In contrast 
class I HDACs are associated with interferon signaling. Interestingly, this is tightly 
interwoven with the STAT enzymes (see paper III) (Falkenberg and Johnstone, 2014). A 
specific HDAC6 inhibitor of class IIb induces ROS production and increase bacterial 
clearance in macrophages (Ariffin et al., 2015). The inhibition of HDACs can hence have 
opposite effects with both pro- and anti-inflammatory activities. Moreover, HDAC inhibitors 
do not only act on histones of the chromatin but also modifies other proteins. Transcription 
factors are often acetylated, and one example is STAT3, which is discussed in paper III and 
in (Yuan et al., 2005). Acetylated Lys685 in STAT3 will aid in dimerization and thereby 
increase transcription of STAT3 regulated genes. ERα as well as HIF-1α also contain lysine 
residues, which have been shown to increase transcription if acetylated (Wang et al., 2001).  
HDAC inhibitors are being evaluated as adjunctive cancer treatment by virtue of their 
potentiation of cytostatic drugs. In addition, they are relevant for other indications, such as 
neurodegeneration and inflammation (Falkenberg and Johnstone, 2014). HDAC inhibitors are 
also implicated in attempts to cure HIV, due to their potential to activate viral replication in 
cellular reservoirs (Shan et al., 2014).  
1.6.1 Entinostat 
Entinostat is an HDAC inhibitor of the benzamide-type. However, chemically it can also be 
defined as an aroylated phenylene diamine (APD), which is further discussed in paper II.  
Entinostat is selective against class I HDACs, i.e. HDAC1-3, with an IC50 of sub µM 
concentration (Lauffer et al., 2013). Entinostat is currently in clinical trials as adjunctive 
treatment in a variety of cancer indications, such as blood cancers and solid tumors.  
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Figure 2. Gene regulation and transcription factors regulating the CAMP gene. Heterochromatin inhibits 
transcription by hiding the genes in tightly packed nucleosomes (a). A transcription factor can bind the DNA and 
facilitates de-condensation by recruiting special chromatin remodeling complexes. Inhibition of HDACs can also 
facilitate the less dense heterochromatin (b). Transcription requires recruitment of several factors to form an 
initiation complex that directs RNA polymerase II (c). Transcription factors known to regulate CAMP gene expression 
are STAT3, thyroid receptor (TR), estrogen receptor (ER), vitamin D receptor (VDR), retinoid X receptor (RXR), 
hypoxia inducible factor 1 (HIF-1), PU.1, C/EBP and glucocorticoid receptor (GR) (d). 
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1.7 IDENTIFICATION OF NOVEL DRUGS 
Novel small molecular compounds to be utilized as drugs are difficult to find. The number of 
molecules that can be synthesized is vast and the numbers of targets of these compounds are 
large. Therefore, combining the large amount of compounds with the large number of targets 
in a rapid, simple and efficient way is desirable. Drugs are being developed in an ‘intelligent’ 
way designed to fit the active site in a given enzyme. This is, however, a difficult task, where 
a crystal structure is needed and thus does not represent the dynamic structure of a protein. 
With computer-aided drug design the limitation of the crystal structure can to some extent be 
circumvented by modeling the structure of a specific enzyme in a computer program and 
even apply dynamic properties to the structure (Sliwoski et al., 2014; Van Drie, 2007). 
Although these computer programs are getting better, protein modeling takes huge processing 
power and the result is difficult to validate. However, when the structure is available, it is 
possible with additional programs to analyze a massive number of compounds for binding to 
the enzyme of interest. This is designated as virtual high throughput screening (HTS) 
(Sliwoski et al., 2014; Van Drie, 2007). For information about methods of computer-aided 
drug design and virtual HTS and the drugs that have been discovered by these methods, 
please see the excellent overviews by Van Drie and Sliwoski et.al. (Sliwoski et al., 2014; Van 
Drie, 2007). The use of various bioinformatic tools is a necessity in research today, but 
nothing beats ‘reality’ and the majority of drugs discovered in the last thirty or forty years and 
also today is through the use of ‘reality’ HTS or by serendipity. However, a good and reliable 
assay is necessary in order to search for novel compounds with biological activity.  
1.7.1 Assay development 
Assays come in many shapes, but there are some general requirements outlined below. 
Overall, the main aim of the selected assay is to reach a result in an easy, fast and cheap 
manner.  
The choice of assay also depends on the amount of information available about the final 
target. For example, in the current work we aimed for induction of a specific peptide without 
knowing which intracellular signaling pathways that are involved. We therefore designed an 
assay as close to in vivo conditions as possible; in this case a so called ‘cell-based assay’.  
Alternatively, if we had been searching for inhibitors of a specific enzyme, it would have 
been better to first produce the enzyme in large amounts. Next, the enzyme would have been 
mixed with compounds from a chemical library to search for inhibition of the chemical 
reaction, as measured by a chromogenic substrate changing the color or absorbance, i.e. a 
‘biochemical assay’ and in this case a ‘colorimetric assay’.     
All techniques can be streamlined and the method chosen must be weighed against a number 
of considerations. What is the biology of the target? Is it an enzyme, a receptor or a gene? 
What equipment is available in the laboratory? What is the background and experience of the 
scientist who is developing the assay? Should the target be inhibited or induced? How many 
compounds shall be screened? The following considerations in assay development are 
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adopted from Huges et.al (Hughes et al., 2011) and they were used when the Luciferase 
construct was designed in paper I: 
1. Consider whether the assay is relevant from a pharmacological point of view. Are 
there known compounds with activity on the target, that can be used for evaluation? If 
so, use these compounds to evaluate whether the assay is responding as in previous 
methods and can be entrusted to identify novel compounds within the desired potency 
range.  
2. Consider that the assay must be stable enough to work within the program of a HTS 
environment. HTS is often done over the time of several days, and a drug screening 
program often lasts for years. It is therefore vital that the assay is reproducible enough 
to give the same response to the controls across both time and plates.   
3. Consider the cost per compound, reagents are expensive and so are plates. The assay 
should be able to be run in microtiter plates. Plates with 96-wells up to 1536-wells are 
available and with more wells less reagents per compound are needed. However, with 
the higher number of wells per plate comes a higher cost in form of automation and 
plate readers.  
4. Consider to evaluate the quality of the assay, which is usually done, by assessing the 
Z’-factor (Zhang et al., 1999). The Z’-factor method measures the span, where a hit 
compound can be detected and contemplates the variance in both positive and 
negative control signals or simply put, it gives a statistical value on the chance of 
detecting a hit. The Z’ factor is a number between zero and one, where 0.5-1 denotes 
an excellent assay. Before the screening endeavor the Z’-factor would be determined 
but also during the run of a HTS the quality is assessed using the Z’-factor by adding 
controls to each plate. This adds the opportunity to follow the quality of the assay in 
time and between plates. The use of the Z’-factor to determine assay quality is also 
discussed in paper I and in the methodology section.  
5. Consider the concentration of solvents and of the library compounds, and how these 
factors influence the assay. Compounds of the library are usually stored and shipped 
in a solvent. This means that in the assay there will be two external parameters 
affecting the system. Therefore the solvent needs to be tested for effect prior to the 
HTS. In the case of dimethyl sulphoxide (DMSO) potential effects are usually not 
observed up to 1 % in cell based assays, while up to 10 % can be used in biochemical 
assays. To test compounds in a library at different concentrations are inefficient and 
the concentration used must be carefully considered. Typically, 1 or 10 µM is used as 
the final concentration in the assay, however, both higher and lower concentrations 
may be used depending on the library, the target and the expected outcome. Lower 
concentrations often give fewer hits, albeit stronger activity upon the target (more 
potent) and reciprocally, higher concentrations give more hits with less activity (less 
potent).  
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1.7.2 Chemical libraries 
The number of possible conformations of molecules almost reaches infinity and hence there 
are very large compound libraries available within the pharma-industry but also commercial 
libraries are available. What library to use is a matter of where the screening takes place, the 
cost per screened compound and whether the intellectual property is well covered.  
The use of a ‘proper’ HTS library challenges the target with compounds far from each other 
in chemical space and often includes a huge number of molecules. More often libraries of 
focused screens are used. A ‘Lipinski's rule of five’ library is an example of a focused library 
and is often utilized to remove the cost of testing molecules that most likely never will be 
used as drugs (Lipinski et al., 1997). The Lipinski's rule of five hints whether a molecule is 
drug-like or falls outside the boundaries set for oral drugs regarding absorption, distribution, 
metabolism, and excretion (ADME). Other focused libraries can be made up of molecules 
that are known to act on targets of similar background or derivatives of a compound known to 
act on the target of interest. The latter case is often the step after the HTS, the hit-to-lead 
phase, where a hit compound is slightly altered with combinatorial chemistry to find an even 
better hit or a lead compound (Hughes et al., 2011). In paper I we used the Prestwick 
chemical library of which all compounds are known to activate various targets. All 
compounds have been through regulatory controls and the safety profile is known for each 
compound. The compounds have also been selected to be of high diversity in molecular 
space. This combination will give the library a high probability for hits but also for hits that 
can be further developed into drugs. Importantly, the Prestwick compounds can also be 
directly turned into repurposed drugs. Repurposing of a drug is efficient from a medical point 
of view, since all the safety studies already have been performed. The perspective of 
patenting the re-purposed drug is however more difficult.  
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2 AIMS OF THIS THESIS 
The main aim of this thesis has been to identify novel inducers and to elucidate the 
mechanism of action of AMP expression in general and more specifically the expression of 
the human cathelicidin LL-37.  
The specific aims are: 
 To establish a methodology for rapid identification of AMP inducers and to identify 
novel inducers and validate them in vitro. (Paper I)  
 
 To evaluate a novel group of AMP inducing compounds and to elucidate how their 
effectiveness are related to the chemical structures. (Paper II)  
 
 To study the LL-37 inducing mechanism of entinostat, a compound identified in 
paper II. (Paper III) 
 
 To investigate the mechanism and signaling pathways involved in PBA and lactose 
mediated induction of the CAMP gene through the use of label free mass 
spectrometry coupled to proteomic analysis. (Paper IV) 
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3 METHODOLOGY 
General aspects: Most methods utilized in this thesis are well established and described 
elsewhere. Western blot and quantitative real-time PCR, immunohistochemistry and cell 
culture work is described in (Kai-Larsen et al., 2007; Sarker et al., 2011) as well as in papers 
I, II, III and IV. Isolation and differentiation of mononuclear cells to macrophages is 
described in paper III as well as how cell lysate fractionation was performed. 
3.1 MOLECULAR CLONING  
Molecular cloning is a collective terminology of methods used in the manipulation of genetic 
material, often combined from different species and by utilizing enzymes with the ability to 
specifically alter DNA. Replication of the genetic material is crucial and almost always 
performed in a host organism, such as Escherichia coli. In this thesis molecular cloning has 
been used to produce the MN8CampLuc cell line and is described in detail in paper I.   
Before early 1970’s, molecular biology and genetics were laden with the fact that genes and 
other genetic information could not be isolated. This notion changed dramatically with the 
finding of bacterial restriction endonucleases and with the identification of the DNA ligases. 
These findings enabled the first joining of recombinant DNA in 1972 and 1973 (Cohen, 
2013; Cohen et al., 1973; Jackson et al., 1972). The amount of discoveries and advances that 
this methodology has brought to science in general cannot be overestimated.  
The starting point of any molecular cloning experiment is the vector or the plasmid, a 
standard DNA backbone with all essential elements needed for replication in bacteria. To this 
backbone other traits are inserted, such as a selection cassette, i.e. an antibiotic resistance 
gene, and a ‘multiple cloning’ site for easy insertion of novel DNA. The variants of the 
backbone are almost endless; there are special backbones for experiments on microRNA and 
special backbones for overexpression experiments and others to be used for bacterial protein 
expression. We utilized a plasmid, pGL-4.26, with a luciferase cassette used for reporter gene 
assays. The plasmid includes an ampicillin
R
 cassette for selection of clones in the bacterial 
host and a hygromycin
R 
cassette for selection in mammalian cells.  
Normally, for the construction of a reporter gene assay, only a small part of the gene 
promoter is inserted in front of the luciferase reporter gene. We, however, had clear evidence 
that part of the regulation of the CAMP gene was located to intron 1. There was also minor 
information on the regulatory elements upstream of the gene and to cover as much of the 
regulatory elements as possible it was decided to keep the reporter gene under as much 
endogenous CAMP gene control as possible. Molecular cloning, especially the steps 
regulating transformation (bacterial uptake) and transfection (mammalian cell uptake) is 
dependent on the size of the plasmid. Transfection efficiency declines exponentially with 
plasmid size above 10 kb. The backbone of the pGL-4.26 plasmid is ~ 6 kb, which left us 
with 4 kb to work with. Fortunately, the CAMP-gene is a rather small gene of only 2 kb, 
including introns. Therefore we decided to incorporate the entire gene into the plasmid and 
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we included a 3 kb stretch of promoter DNA upstream of the gene (Figure 3) and although 
this reduced the transfection efficiency (final size ~10.7 kb), we did not want to miss 
potentially important regulatory elements. For the cloning we utilized a seamless cloning kit 
allowing for insertion of fragments into a plasmid without the use of restriction enzymes. 
Instead we introduced long overhangs by PCR on both the insert and the plasmid (A1-A4 in 
Figure 3). These fragments were mixed with an enzyme that facilitated recombination, i.e. 
seamless cloning. This technique allowed for insertion of the CAMP gene fragment in frame 
with the luciferase. It also permitted us to easily remove the stop codon of the CAMP gene 
and the start codon from the luciferase gene. The final product would produce a fusion 
enzyme consisting of proLL37-Luciferase under control of all regulatory elements of the 
CAMP gene (Figure 3). By removing the start codon of the luciferase gene we asserted a low 
background luminescence signal, since all other possible start codons were located in the 
CAMP gene. Before the genomic integration procedure we transiently transfected the, human 
colonic epithelial, cell-line HT-29 with the construct and verified that the construct indeed 
was able to produce functioning luciferase. Stable integration demands a linear DNA 
fragment and a circular plasmid will randomly be linearized prior to integration. By actively 
linearizing the plasmid prior to transfection the chances of a successful experiment were 
highly enhanced. The vector utilized could be linearized within a 3.1 kb stretch of DNA. If 
the linearization would have been allowed to occur randomly, only 29 % of all integration 
events would have been functioning and 68 % of all hygromycin resistant clones would be 
identified as false positives. We used the restriction enzyme Spe1 for linearization (Figure 3).  
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Figure 3. Schematic representation of the vector used in paper I, including genomic integration, transcriptional and 
translational end product. The pGL-CampLuc vector was produced by fusion of the CAMP gene into a pGL-4.26 
vector (a). After stable transfection and selection using hygromycin, the fusion gene produces fusion CampLuc mRNA 
under endogenous-like CAMP gene control (b). The ensuing fusion protein was designated proLL37-Luciferase and 
expression can be quantified utilizing Luciferin and a luminometer (b). 
At the end of our experiment we obtained a high success rate and could choose between 
several clones with different phenotypes. The MN8CampLuc cell line was propagated from a 
clone of moderate background and with a potent response to known LL-37 inducers.  
The MN8CampLuc cell line has been invaluable to all of the following work in this thesis. 
However, any reporter cell line has certain drawbacks, which needs to be taken into 
consideration. The stable integration is not under endogenous control and the place of 
genomic insertion is random. Thus, stable integration can alter the phenotype of the cells and 
affect specific responses. It has therefore been important to always verify our results in the 
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parental cell line HT-29. At the time of the construction, a novel technique of zinc finger 
nucleases, which allowed for exact insertion into the genome, arrived on the market. This 
method enabled the possibility to insert luciferase in frame with the endogenous CAMP gene 
and actually have full endogenous control over the reporter gene insertion site. The technique 
was however very expensive and time consuming. Therefore, we did not continue with site 
specific integration of the luciferase-reporter construct. Today, on the other hand, with the 
rapid development of the CRISPR/Cas9 technology, site specific integration would be 
possible in a fast and easy way (Cong et al., 2013; Jinek et al., 2012; Jinek et al., 2013; Mali 
et al., 2013). 
3.2 CHROMATIN IMMUNO PRECIPITATION  
Chromatin Immuno Precipitation (ChIP) coupled to qPCR is a technique developed to 
analyze the recruitment of proteins to DNA or to additional proteins bound to DNA. In short, 
the method allows for discriminating between increased or decreased binding of a protein to a 
general specified part of DNA. The prerequisites demand that a protein of interest and a 
stretch of DNA is selected for analysis of differential binding.  
In this work we used ChIP in paper III for determining whether STAT3 and HIF-1α were 
recruited to the CAMP gene promoter upon entinostat stimulation. Cells were treated with 
entinostat or the vehicle control. In this case cells were fixed using formaldehyde, which 
caused covalent binding of DNA and proteins in proximity to each other. Next, cells were 
lysed and the lysates, which contained a chromatin mixture of DNA and bound proteins, was 
sonicated. The sonication broke DNA into random fragments of approximately 400-500 bp. 
The size of the fragments can be regulated by altering sonication cycles, pulse lengths and 
sound intensity. These 400-500 bp DNA fragments carried bound proteins of various sorts 
and by utilizing a specific antibody, in this case against HIF-1α and STAT3, only fragments 
that carried these proteins were fished out. This procedure resulted in an enrichment of 
fragments with bound HIF-1α or STAT3. Next, the fixation was reversed and the DNA 
fragments were purified and separated from the proteins. By utilizing primers close to the 
putative binding site of the particular protein, we determined if there was an increase in 
binding in treated cells compared to unstimulated cells.  
The technique is invaluable when it comes to determine if a recruited protein occurs at the 
promoter of your gene of interest. However, there are some important limitations to this 
technique. First, the protein of interest must be known and there has to be specific antibodies 
against it. The general binding site would also have been identified. There is the possibility to 
construct several primer pairs that cover a large part of the DNA if the binding site is 
unknown. The method does require some material though and therefore the number of primer 
pairs cannot be too large. Another drawback with ChIP-analysis is that it cannot distinguish 
between stationary and recruited transcription factors. For example, the VDR is considered to 
be stationary on the CAMP gene, i.e. it acts as an inhibitor of transcription until it is activated 
by the ligand calcitriol (Seuter et al., 2013). This means that although the gene is regulated by 
VDR, the recruitment seen as the difference between stimulated and unstimulated cells will 
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not be visible, since there is no increase of VDR binding. Finally, ChIP-analysis is highly 
sensitive to methodological errors, due to many washing steps, small volumes and the risk of 
losing material during the many experimental parts. Thus, there is a need to be careful and to 
include proper controls for all steps in order to obtain reliable and reproducible results.  
Utilizing ChIP with subsequent deep sequencing (ChIP-seq) will increase costs, but the 
problem with stationary TFs will be circumvented, since the difference is compared to both 
the average signal and to the unstimulated cells. Interestingly, read densities, utilizing ChIP-
seq is indicative of the protein/DNA binding affinity. This allows for comparison of 
preferential protein binding to different promotors and could possibly be used to compare the 
binding of, for example, VDR to different genes encoding AMPs. The binding sites that are 
needed to be predicted before ChIP-qPCR can instead be observed in the results from ChIP-
seq, and the exact binding site can be determined within 10 bp (Jothi et al., 2008). ChIP-seq is 
limited to sequencing read lengths and to repetitive regions in the genome and of course to 
the cost. The limitations are likely to be circumvented with the new generation of sequencing 
techniques in addition to more powerful computers and software. 
Finally, most datasets from deep sequencing projects are uploaded to public repositories and 
are free of charge for other scientists to use. Much information can be gained from these 
repositories and should be utilized.  
3.3 PROTEOMICS COUPLED TO PATHWAY ANALYSES  
In paper IV we utilized label-free quantitative mass spectrometry (MS) to illuminate the 
proteome of cells and how it differs with treatment. The benefit of analyzing proteins and 
protein levels are to circumvent all method errors that follow transcription dependent 
methods. With quantitative MS there is no translational regulation or transcript stability to 
account for and moreover, proteins are the functional end product. Utilizing quantitative MS 
over gel based methods, such as 2D-DIGE is rapidly winning ground. The hands on time and 
the time to obtain results are significantly shorter and 2D-DIGE is unable to map 
hydrophobic, high molecular weight proteins with extreme isoelectric points. However, the 
ability of quantitative MS to identify full length proteins and especially to separate between 
post translational modifications is still difficult (Arentz et al., 2015). Another drawback is the 
inability to identify ‘absence’ in quantitative MS; i.e. it is very difficult to prove the presence 
of ‘on-off’ proteins. Comparing label free MS method to labeling MS methods, such as stable 
isotope labeling by amino acids in cell culture (SILAC) or isotope tags for relative and 
absolute quantification (iTRAQ) mostly favors label free MS. As with any labeling chemistry 
there is always the preference for certain reactions, hence an introduced error in labeled 
entities and in results. The number of experimental steps is also much lower in the label free 
setting, which reduces costs. The normality in growing cells with ‘unnatural’ isotopes can 
also be discussed. The only drawback of label free quantitative MS is the need of an 
instrument with high enough resolution (Bantscheff et al., 2007; Distler et al., 2014).  
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Finally, the results we obtained were analyzed by the use of QIAGEN’s Ingenuity® Pathway 
Analysis. This way of allowing a computer program to map and analyze the vast data set 
streamlined the whole process and rapidly allowed for identification of potential regulatory 
pathways. We utilized the MN8CampLuc cell line to rapidly sort the pathways into LL-37 
unrelated but affected pathways and of signaling pathways regulating the expression of the 
CAMP gene.    
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4 RESULTS AND DISCUSSION 
Antimicrobial peptides were early appreciated for their involvement against infection and 
inflammation. Therefore, much effort has been focused on possible therapeutic applications 
using the peptides as treatment per se. However, this approach has so far not been very 
successful. There have been several attempts to administer the peptides topically in various 
clinical settings, however, despite several attempts none has reached the market so far (Fox, 
2013; Moore, 2003).  
If the body instead could be ‘forced’ to produce more of the peptides at the site of infection 
many drawbacks of exogenous administration could be avoided. Since many AMPs are 
regulated together (Sarker et al., 2014) it is tempting to search for inducers as a novel 
approach against infections. It is known that PBA can induce LL-37 and was initially 
developed to treat urea cycle disorders and thus has been evaluated for safety in humans. This 
means that PBA can be ‘repurposed’ on a new indication without the need of safety 
evaluation and in that manner be introduced on the market.  
The exact mechanisms behind the regulation of AMPs are still largely unknown. With a 
better understanding of the mechanisms we can find more effective inducers and choose the 
inducer that activates a preferred pathway and hence optimize effects and reduce side effects.     
4.1 PAPER I: BOOSTING INNATE IMMUNITY: DEVELOPMENT AND 
VALIDATION OF A CELL-BASED SCREENING ASSAY TO IDENTIFY LL-37 
INDUCERS 
Rationale: To search for novel inducers of LL-37 expression in an efficient manner, therefore 
it was important to develop a simple, fast and cheap screening-system. 
Aim: To develop a cell-based luciferase reporter-system, which could be used for HTS of 
chemical libraries. 
Results: The colonic epithelial cell line HT-29 was stably transfected with a Luciferase 
construct, where the CAMP gene was seamlessly integrated with the luciferase gene; i.e. 
luciferase will only be transcribed together with the CAMP gene. The regulation will 
resemble the endogenous regulatory machinery, since a large (3 kb) part of the promotor as 
well as all introns were preserved. The construct was verified to be fully integrated and with 
only one copy into the genome. The expected protein product was a fusion protein of proLL-
37 (hCAP-18) and Luciferase. This new cell line was designated MN8CampLuc and was 
tested for responsiveness to known inducers of the CAMP gene. The cell line responded in a 
similar manner as the parental cell line HT-29 to stimulation by vitamin D, LCA, lactose, 
butyrate and PBA. During the work, a new paper by Park et.al showed that endoplasmic 
reticulum stress induced LL-37 (Park et al., 2011). Thus, addition of tunicamycin, an 
endoplasmic reticulum stress inducing compound, to the MN8CampLuc cell line resulted in 
induced expression of LL-37, which was in line with the reported result.  
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After having confirmed that the cell line indeed was responding as expected to known 
inducers, a small panel of HDAC inhibitors and derivatives thereof was screened. All tested 
compounds were able to induce the expression of proLL37-Luciferase to the same extent or 
more prominent than the positive control PBA. To further confirm the validity of these novel 
inducers, the parental cell-line HT-29 was screened with these compounds and similar results 
were obtained.  
Prior to HTS, the assay needed to be quality assessed, utilizing the industrial standard Z’-
factor (described in 1.7.1 Assay development). The MN8CampLuc cells scored 0.7 as Z’-
factor, which indicated that the assay was well adjusted for HTS purposes. We decided to use 
the assay in in 96 well plate format in order to save time, reagents and hands-on-time.  
The Prestwick library consists of 1200 compounds and was delivered in 15 plates with 
column 1 and 12 empty for controls. Negative and positive controls were added to the empty 
columns. Cells in 15 different 96-well plates were treated with the compounds in a final 
concentration of 10 µM and incubated for 24 hours. The next day each well in the 15 plates 
were inspected under the microscope and marked in case for signs of cytotoxicity. The cells 
were then washed, lysed and measured for luciferase activity. Fold induction for each 
compound was calculated for each plate by dividing the signal of the compound with the 
average of the four vehicle controls present on each plate. Hits were determined to be outside 
of three standard deviations of the average fold induction for all compounds. The temperature 
in the plate reader slowly increased with time, which correlated to an increase in luciferase 
signal intensity. To circumvent this, the calculation of the hit threshold was performed on the 
fold inductions, as described in 1.7.1 Assay development, rather than on the raw signal. We 
got 18 positive hits which is a 1.5 % hit rate, a typical number from this type of focused 
libraries.   
The continued quality assessment of the assay during the screening-procedure gave 15 
Z’-factor values ranging between 0.7 and 0.91 which was more than adequate (Figure 4). 
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Figure 4. HTS of the Prestwick chemical library. Each circle denote the fold induction for one out of 1 200 compounds 
in the library. Grey lines indicate the cut off for negative and positive hits, respectively. Cut off was calculated as the 
average of all compounds plus or minus three standard deviations. Thus, 18 compounds were evaluated to induce 
proLL37-Luciferase.       
HTS is often associated with some false positive signals and therefore it is prudent to re-run 
the hits. A dose-response experiment would allow both optimal concentration and false 
positive determinations. Out of the 18 hits, 7 could not be reproduced. At first this was 
considered to be false positives, however, the second experiment was run with 1% DMSO in 
order to have the high concentrations of the compounds in the dose-response experiment. In 
the HTS, on the other hand, the DMSO concentration was kept at 0.1 %, therefore a re-run 
with the “false positives” at 10 µM with 0.1 % DMSO showed increased proLL37-Luciferase 
expression. Notably, cathelicidin is induced by ER-stress as shown by Park et.al (Park et al., 
2011), and it has also been demonstrated that DMSO can act as an endoplasmic reticulum 
stress reliever (Song et al., 2012). In account of these experiments the notion that DMSO can 
attenuate endoplasmic reticulum stress induced cathelicidin expression is a likely possibility 
for the obtained results.   
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Since the assay is a cell based system with a reporter construct there is a chance that the 
responses are due to a new phenotype introduced by the transfection. Therefore it is important 
that the hits can be verified in the parental cell line. The validation was performed on seven of 
the 11 confirmed hits. Four hits, 5-Azacytidine, Azathioprine, Thioguanosine and 
Mercaptopurine, were rejected for further analysis since their safety profile would make them 
unsuitable to treat infections. Azathioprine and Mercaptopurine are used to induce immune 
suppression and the other two for treatment of late stage cancers, in which the safety profile is 
not that restricted. The seven remaining compounds were used to stimulate the parental HT-
29 cell line in a dose-range around the optimal concentrations obtained in the reporter cell 
line dose response experiment. Three out of these seven compounds were confirmed as 
inducers of the CAMP gene also in the parental cells.  
In total, the two small screening-experiments utilizing the Prestwick library and selected 
HDAC-inhibitors produced five novel compounds with potent CAMP-inducing capacity: 
tiratricol, clobetasol and auranofin from the Prestwick library along with isovaleric- and 
isobutyric-acid from the screening of HDAC inhibitors.  
Tiratricol is an analog of T3, the active form of thyroid hormone, and the thyroid hormone 
pathway was found to be upregulated as described in paper IV, where we also could show 
that T3 in fact induced CAMP gene expression. We know that many immune genes are 
regulated by thyroid hormones, however despite several attempts we have not been able to 
reproduce the T3 results on additional cells responding to T3, such as primary PBMC’s and 
macrophages.  
Clobetasol is a corticosteroid also known to activate the glucocorticoid receptor (GR), which 
has been shown to downregulate AMP expression (Kulkarni et al., 2016). Notably, out of 17 
compounds in the Prestwick library with glucocorticoid activity, only clobetasol induced LL-
37. Thus, the induction exerted by clobetasol is likely very specific. The mechanism is still 
unknown and whether the action is mediated through the GR is not determined at this point 
and will be the subject of follow-up experiments in our laboratory.  
Lastly, we also identified auranofin, an organo-gold compound used to relive symptoms in 
rheumatoid arthritis. Auranofin is known to act on both nuclear related factor 2 (Nrf2) and 
NF-κB (Kim et al., 2010; Nakaya et al., 2011), however, neither of these pathways are likely 
to induce LL-37 to any excess. NF-κB has been demonstrated to regulate cathelicidin (Li et 
al., 2009; Park et al., 2011), however, in paper III, the pTRAF vector was used to identify 
entinostat as an inducer of HIF-1α. The same experimental setup also enabled determination 
of NF-κB and Nrf2-activation. Utilizing additional compounds that activated these pathways 
more than auranofin, we could not observe any induction of CAMP gene expression (data not 
shown), hence auranofin most likely increases LL-37 expression via a pathway separate from 
NF-κB and Nrf2. Interestingly, auranofin has been found to be effective against both 
methicillin-resistant Staphylococcus aureus (MRSA) and Mtb. A likely mode of action of 
auranofin against MRSA is through the activation of the redox pathway (Harbut et al., 2015), 
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but increased AMP-expression may be a possible explanation (Dean et al., 2011; Pence et al., 
2015; Sass et al., 2008). 
4.2 PAPER II: HIGHLY POTENT INDUCERS OF ENDOGENOUS 
ANTIMICROBIAL PEPTIDES FOR HOST DIRECTED THERAPY OF 
INFECTIONS 
Rationale: Most compounds initially tested in the MN8CampLuc cell line showed moderate 
inducing ability, and somewhat higher than for PBA. However, one compound, Entinostat, 
exhibited potent AMP-inducing properties. This prompted further investigation if compounds 
with similar structural features, (aroylated phenylene diamines, APDs) also were potent 
inducers. Therefore it was of importance to investigate structural requirements and to produce 
inducers with alternative structures in order to be able to select candidates with a suitable 
activity vs toxicity profile as well as to obtain proof of concept in an animal infection model.  
Aims: 1) To develop a number of different APDs and related compounds. 2) To obtain 
information on how structural features affect the ability to induce LL-37 by utilizing the 
MN8CampLuc cell line as the first assay. 3) To obtain information if the activity is 
reproducible in the parental cell line HT-29 and to investigate if addition of vitamin D affects 
the induction. 4) To obtain in vivo data in a rabbit model of Shigellosis, showing the potential 
efficacy of entinostat.  
(Numbers refer to compounds depicted in paper II and in Figure 5. 
During the evaluation process of the MN8CampLuc cells in paper I, several experiments with 
different possible inducers were performed. Butyrate, PBA and the two newly identified 
HDAC inhibitors from paper I proved that HDAC-inhibition can be associated to LL-37 
induction. Therefore, the structurally unrelated second generation HDAC inhibitors, 
vorinostat and entinostat (5), were tested in the MN8CampLuc cell line. Despite being an 
HDACi that is several orders of magnitude more potent than PBA, vorinostat (not depicted) 
induced proLL37-Luciferase expression to approximately the same level as PBA. Entinostat 
(5), however, outperformed all previously identified inducers of LL-37 expression. 
Furthermore, the effect occurred at a concentration about 1000 times lower than any other 
inducer hitherto tested. 
A number of different compounds with similar structures were synthesized with variation of 
substituents and other structural features. Thereafter these were analyzed for proLL37-
Lucifease induction and the consensus was that the general structure needed for induction 
was the APD moiety (boxed molecule in Figure 5). Thus, a structurally new class of inducers, 
APDs, was discovered. It was found that many of the novel APD-compounds were 15-20 
times more potent than PBA (1) to induce proLL37-Lucifease and at 100-1000 times lower 
concentration.  
From the structure-activity studies it became clear that the substituents of the aroyl moiety (2-
4, 6-9) influenced the inducing ability. Also the diamine moiety was crucial for induction 
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since neither nitrogen could be exchanged for oxygen without complete loss of activity (10, 
11, 13). Neither could the ring structure be exchanged for an aliphatic diamine (14, 15).  
Substitutions in the aroyl moiety were more forgiving with respect to loss of activity. On the 
other hand, removal of the carbonyl group resulted in a pronounced reduction in activity (16).  
One of the derivatives was able to induce expression of proLL37-Luciferase to somewhat 
higher levels than entinostat, albeit at a higher concentration. This could be due to a less toxic 
substituent for this compound, allowing the dose response to rise above that of entinostat.  
Compound 8 lacked the aroylated substituent and had reduced potency, and was less toxic 
than 5. However, potency is often rejected for less toxic compounds and both compound 8 
and 9 were considered to be possible leads for future drug development.   
To obtain in vivo data, entinostat was used to treat rabbits in a model of shigellosis. The 
results clearly demonstrated that entinostat improved clinical symptoms in the rabbit, reduced 
the infectious burden and induced cathelicidin-expression in the gut epithelial layer, as shown 
by immunohistochemistry. It should be mentioned that entinostat also is known to activate 
other parts of the immune system i.e. to reduce the levels of forkhead box P3 (Foxp3) in 
regulatory T-cells and hence activate a more pro-inflammatory and possibly a more 
antibacterial response (Shen et al., 2012). Entinostat has also been demonstrated to regulate 
immunity by inducing the unfolded protein response pathway, also called endoreticulum 
stress (Gameiro et al., 2016). Whether the mechanism behind the beneficial effects is due to 
induction of AMPs or involves a combination of additional immune functions needs to be 
explored. However, our comparison with even more potent HDAC inhibitors suggests that 
HDAC inhibition is not the major mechanism behind the induced expression of LL-37.   
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Figure 5. Chemical structures of the APD compounds tested for induction of LL-37. Number 1 is PBA and number 5 
is entinostat. The boxed structure in the left top corner indicates the general structure of an APD. 
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4.3 PAPER III: ENTINOSTAT UP-REGULATES THE CAMP GENE ENCODING 
LL-37 VIA ACTIVATION OF STAT3 AND HIF-1 TRANSCRIPTION FACTORS 
Rationale: Entinostat was found to be our most potent inducer of LL-37 expression. 
However, the mechanism behind this induction has not been investigated. If the involved 
transcription-factors could be identified, we could learn more details of LL-37 induction but 
also obtain insight how additional AMPs are regulated by the same pathway.  
Aim: To identify transcription factors involved in entinostat-mediated induction of LL-37 and 
potential co-regulation with other AMPs.  
Results: The entinostat inducing effect was discovered during the evaluation of the 
MN8CampLuc cells in paper I. These results were confirmed and further evaluated for dose-
response and kinetics in the parental cell line HT-29. The optimal time for induction was 
found to be 24 h, while the optimal dose was defined as 2.5 µM, based on the balance 
between optimal effect and minimal toxicity. We also hypothesized that entinostat would 
upregulate several AMPs and therefore we investigated expression-levels for human β 
defensins. A combined action of several AMPs with different mechanism of action, leading 
to a multiple attack to the pathogen would minimize the development of bacterial resistance. 
Notably, we found that entinostat induced hBD1, an important peptide in epithelial defense 
(Prado-Montes de Oca, 2010), whereas HBD2 was not affected.  
Entinostat has been shown to have potent immunomodulatory effects. Shen et.al reported that 
entinostat inhibits the effect of T regulatory cells by acetylation and activation of STAT3, 
which in turn de-activated Foxp3, the master regulator of T regulatory cell development (Hori 
et al., 2003; Shen et al., 2012). To elucidate whether STAT3 could be involved in AMP-
expression, the CAMP gene was scanned for STAT3 binding elements. Interestingly, several 
STAT3 binding sites were identified in the promoter of the CAMP gene.  
Further, the induction of CAMP gene expression could be repressed using both short hairpin 
RNA (shRNA) and a STAT3-inhibitor. Additional evidence for STAT3-activation by 
entinostat was obtained by the observation of increased expression of ‘B-cell lymphoma 2’ 
(Bcl2), a STAT3 downstream target gene (Carpenter and Lo, 2014) and by Western blot 
analysis on nuclear extracts, where STAT3 appeared to be accumulated in the nucleus after 
entinostat-treatment. However, no binding of STAT3 to the CAMP gene could be detected, 
utilizing the ChIP technique. Hence, it was concluded that STAT3 was a part of the 
regulatory pathway of LL-37-expression, albeit it was acting as a second mediator rather than 
binding directly to the CAMP gene promoter. 
Given that HIF-1α, a transcription factor involved in cellular response to hypoxia, has been 
shown to regulate LL-37 expression, we hypothesized that HIF-1α might be activated by 
entinostat treatment and thereby increase expression of LL-37. Indeed, we found binding 
elements for HIF-1α in the CAMP gene promoter and stimulation by entinostat caused 
induced expression of HIF-1α mRNA in HT-29 cells. To test whether this increase in mRNA 
was associated with an increase in active HIF-1, the vector pTRAF was utilized (Johansson et 
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al., 2015). This vector contains the gene for a fluorescent protein under the control of tandem 
repeats of HIF-1 transcription factor binding sites. Therefore, entinostat was used to stimulate 
HEK293 cells transfected with the pTRAF vector, which revealed that HIF-1 activation was 
indeed increased upon entinostat treatment. In addition, utilizing ChIP, HIF-1α was shown to 
be enriched on the CAMP gene upon stimulation with entinostat.     
Furthermore, shRNA experiments indicated that knockdown of HIF-1α completely abrogated 
entinostat elicited induction of the CAMP gene. Interestingly, shRNA directed towards 
STAT3 inhibited the entinostat induced HIF1A gene expression, suggesting an important 
cross-talk between STAT3 and HIF-1α.  
The following mechanism of LL-37 induction elicited by entinostat is suggested. Entinostat 
inhibits deacetylation of STAT3 and hence increase the amount of active STAT3, which 
translocates to the nucleus where it acts as a dual activator by binding and activating 
transcription of the HIF1A gene but also by stabilization of the HIF-1α subunit, which then in 
turn will bind to the promoter of the CAMP gene and initiate transcription (see Figure 7). 
Finally, we had access to whole-blood derived macrophages from a HIES-patient, with a 
causative STAT3 mutation. Interestingly, entinostat did not induce CAMP gene-expression in 
these cells as compared to two healthy control individuals, which lend further support to the 
observation that STAT3 is important for LL-37 expression (Figure 6).  
 
Figure 6. Entinostat elicited induction of CAMP gene expression is reduced in macrophages derived from a HIES 
patient compared to healthy individuals. 
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Figure 7. Mechanism of entinostat induced LL-37 expression. Entinostat inhibit HDAC activity, which shifts STAT3 
towards a more active state (a). Acetylated STAT3 is translocated to the nucleus and activates transcription of the 
HIF1A gene (b). Increased transcription of HIF1A will lead to more HIF-1α translated protein (c). Acetylated STAT3 
inhibits ubiquitination and hence degradation of HIF-1α (d). Stabilized HIF-1α then binds to the CAMP gene and 
initiates transcription (e), leading to downstream translation of the pro-peptide of LL-37, hCAP-18 (f). 
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4.4 PAPER IV: LABEL-FREE QUANTITATIVE MASS SPECTROMETRY 
REVEALS NOVEL PATHWAYS INVOLVED IN LL-37 EXPRESSION 
Rationale: It was found that co-stimulation with lactose and PBA, exhibited a synergistic 
effect on AMP-inducing properties. However, there was no information on the mechanism 
governing this potent induction. Identifying the mechanism could potentially lead to novel 
inducing compounds.  
Aim: To perform a proteomic screen on cell lysates from HT-29 cells stimulated with 
vehicle, lactose, PBA or a combination of PBA-lactose and to use bioinformatic methods to 
map the proteomic data on regulatory pathways. 
In previous work from our group it was demonstrated that a synergistic induction of CAMP 
gene expression occurred upon combined stimulation with PBA and lactose (Cederlund et al., 
2013).  
To elucidate the mechanism behind this induction, cells were treated with a combination of 
PBA and lactose or with each compound, separately. Next, the cell lysates were prepared and 
analyzed, utilizing Label-Free Quantitative MS to determine the complete proteome of these 
cells. More than 1300 proteins were identified, quantified and protein quantities were 
normalized to the protein content of untreated cells. Proteins recognized to be up- or 
downregulated were mapped to the ingenuity knowledgebase (IKB) and pathways were 
predicted, utilizing the ingenuity pathway analyzer (IPA). IPA also assigned significance 
values to the suggested pathways and ranked them accordingly. Utilizing the MN8CampLuc 
cell line developed in paper I 11 pathways were suggested as activated by IPA and were 
evaluated by treating the cells with either agonists or antagonists, to crucial components of 
the identified pathways. Three pathways were induced or blocked with specific agonists and 
antagonists, utilizing MN8CampLuc cells: i.e. the thyroid hormone receptor/retinoid X 
receptor (TR/RXR) pathway, the eicosanoid signaling pathway and the steroid biosynthesis 
pathway. Stimulation of MN8CampLuc cells with the active thyroid hormone (T3) and the 
proform (T4) resulted in increased luminescent signals. Moreover, the combination of lactose 
with T3 and T4 indicated an additive effect, whereas PBA and T3 exhibited a more 
synergistic effect. Notably, the parental cell line HT-29, did not respond toT4-stimulation, 
while T3 induced CAMP gene expression within the short span of 6 h of stimulation. Thus, 
these results indicated an important difference between the reporter cell-line and the parental 
cells. mRNA degradation is a regulatory pathway often applied to immune genes and it is 
possible that the CAMP gene is regulated this way and that the extended mRNA of the 
CampLuc fusion gene is more stable and hence prolong the optimal time of induction (Schott 
and Stoecklin, 2010). Also consider the time lag between transcription and translation as well 
as the stability of mRNA versus protein. At this point, we cannot explain why T4 failed to 
produce a response in the parental cells, but we plan to elucidate the details in future projects.  
T3 is a ligand of the thyroid hormone receptor (TR), and it is known that HDAC inhibitors 
can acetylate various transcription factors. Sanchez-Pacheco et al. reported that the TR can be 
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activated via acetylation, which could explain the synergistic effect of T3 combined with the 
HDAC inhibitor PBA (Sanchez-Pacheco et al., 2009). 
The Eicosanoid signaling pathway was examined using several antagonists of eicosanoid 
synthesis. MN8CampLuc cells were treated with PBA and lactose separately or in 
combination and mixed with the antagonists. We found that inhibition of cyclooxygenase-2 
(COX-2) was enough to significantly reduce PBA/lactose induction of proLL37-Luciferase 
expression and this could be validated in the parental cell line HT-29, utilizing the COX-1/2 
antagonist acetylsalicylic acid (ASA). Given that COX-2 inhibition would deplete the levels 
of PGE2, addition of downstream prostaglandin E2 (PGE2) would rescue CAMP gene 
expression. However, we could not prove this hypothesis in our experiments. One 
explanation for this unexpected result is that the eicosanoid signaling pathway is a 
downstream target with an AMP inducing feed-back mechanism since cathelicidin has been 
demonstrated to induce the production of both COX-2 and PGE2 (Chamorro et al., 2009). 
Another explanation is that there are other COX-2 generated lipid products that are 
responsible for the regulation. Bernard and Gallo have demonstrated that hBD2 and hBD3 
also are COX-2 regulated and that the lipid products PGD2 and 15-deoxy-∆12,14-PGJ2 is 
inducing these defensins (Bernard and Gallo, 2010). Interestingly, Park et al. introduced 
sphingosine-1-phosphate as a key inducer of human cathelicidin and there are indications that 
sphingosine-1-phosphate increases expression of COX-2 (Hsu et al., 2015; Park et al., 2016; 
Park et al., 2014; Rumzhum et al., 2016; Volzke et al., 2014). There are additional links 
between lipid mediators and LL-37, including the interconnected circuits of activation and 
production of LL-37 and leukotriene B4 (Wan et al., 2011; Wan et al., 2007; Wan et al., 
2014a).  
The steroid biosynthesis pathway was also probed by inhibition studies on the MN8CampLuc 
cells. PBA and lactose, separately and in combination, were co-incubated with Simvastatin, 
an inhibitor of HMG-CoA reductase, which would block the production of cholesterol and 
isoprenoids. Simvastatin inhibited CAMP gene induction by PBA/lactose and the effect of 
PBA per se, but not the effect of lactose. The results were validated in the parental cell line 
HT-29, with the difference that the effect of lactose mediated induction also could be 
inhibited by simvastatin. The pathway was independent of the downstream products 
mevalonate and cholesterol since addition of these compounds did not rescue induction of the 
CAMP gene. These experiments suggest a HMG-CoA dependent but cholesterol-independent 
regulation of LL-37 expression. More experiments must be performed to prove this fact but 
there are indications that statins may exhibit anti-inflammatory effects. Statins have been 
shown to affect several signaling pathways, including the NF-κB, AP-1, and HIF-1 pathways, 
which  all are important for the regulation of different AMPs. Interestingly, all these 
pathways are down-regulated by statins, which is somewhat in line with our results (Ganz, 
2003; Kida et al., 2006; Peyssonnaux et al., 2005; Rius et al., 2008; Tousoulis et al., 2014).  
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5 CONCLUSIONS 
In conclusion, our results indicate that LL-37 is part of a complex regulatory network and is 
not merely a response to infection and wounding. It seems that LL-37 and other AMPs are 
carefully regulated also during non-stress situations in order to reach homeostasis between 
the host, the commensal and the pathogenic microbiota.  
 Paper I: A well functioning assay was produced and 5 novel inducers of LL-37 
expression were reported.  
 
 Paper II: Entinostat was found to be a potent inducer of LL-37 expression, however, 
the inducing mechanism was only in part due to HDAC inhibition.Altering the 
chemical structure of entinostat displayed which parts of the molecule that was 
important for achiving induction.  
 
 Paper III: By combining several classical molecular techniques we could conclude 
that LL-37 was regulated by entinostat through the transcription factors HIF-1 and 
STAT3. We also showed that entinostat induced LL-37 expression was impaired in a 
HIES patient with a known STAT3-mutation.   
 
 Paper IV: Utilizing label free mass spectrometry we have gained full insight into how 
different stimuli alter the proteome of the cell populations. Strategic use of proteomic 
pathway analysis tools and quick examination of pathways utilizing the 
MN8CampLuc cells showed that this methodology is a resonable alternative to large 
HTS. We could demonstrate that three of several proposed pathways indeed regulated 
LL-37 expression.  
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6 FUTURE EXPERIMENTS OR THINGS I WOULD HAVE 
LIKED TO DO 
There are several experiments that could be performed to gain more insight into the 
regulating pathways of AMPs in general and for LL-37 expression in particular.  
1. Since HDAC inhibitors are potent inducers of LL-37 but the detailed mechanism of action 
remains elusive, I suggest that a screen of a larger HDAC inhibitor library is investigated. 
Thereby, a better and more specific understanding of the role of HDAC-inhibition in the 
regulation of AMP-expression can be gained.  
2. Another way to further dissect the mechanism could be to alter the chemical structure of 
entinostat to obtain a compound with retained LL-37 inducing activity but with no HDAC-
inhibitory activity.   
3. The development of CRISPR/CAS9 is a true revolution in molecular biology and enables 
rapid gene-editing. This technique could be used to both knockdown and knock in genes 
important for AMP expression, which will greatly advance the knowledge of AMP 
regulation.  
4. To obtain additional information on transcription-factor of relevance for AMP-expression, 
there are several new and powerful techniques available. For example, The use of enChIP 
coupled to MS, a method for capturing specific regions of DNA, utilizing CRISPR/CAS9 and 
ChIP, followed by analysis of the protein composition in this region could also be of great 
value to deciphering which factors drive or inhibit AMP transcription (Fujita and Fujii, 2013). 
In addition, ChIP-seq is another powerful method to find transcription-factors. Many 
experiments using this method have been performed where different stimuli and different 
antibodies have been used, all relevant for AMP expression. Notably, these data are often 
made available and can be collected from various web-based depositories. These data-sets 
can be re-evaluated with regard to AMP-expression. Most likely, there is a wealth of relevant 
information available in silico.  
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